Polypeptides Having Acetylxylan Esterase Activity And Polynucleotides Encoding Same

ABSTRACT

The present invention relates to isolated polypeptides having acetylxylan esterase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.12/327,347, filed Dec. 3, 2008, which claims the benefit of U.S.Provisional Application No. 60/992,995, filed Dec. 6, 2007, whichapplication is incorporated herein by reference.

REFERENCE TO A SEQUENCE LISTING

This application contains a Sequence Listing in computer readable form.The computer readable form is incorporated herein by reference.

REFERENCE TO A DEPOSIT OF BIOLOGICAL MATERIAL

This application contains a reference to a deposit of biologicalmaterial, which deposit is incorporated herein by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to isolated polypeptides havingacetylxylan esterase activity and isolated polynucleotides encoding thepolypeptides. The invention also relates to nucleic acid constructs,vectors, and host cells comprising the polynucleotides as well asmethods of producing and using the polypeptides.

2. Description of the Related Art

Plant cell wall polysaccharides constitute generally 90% of the plantcell wall and can be divided into three groups: cellulose,hemicellulose, and pectin. Cellulose represents the major constituent ofcell wall polysaccharides. Hemicelluloses are the second most abundantconstituent of plant cell walls. The major hemicellulose polymer isxylan. The structure of xylans found in cell walls of plants can differsignificantly depending on their origin, but they always contain abeta-1,4-linked D-xylose backbone. The beta-1,4-linked D-xylose backbonecan be substituted by various side groups, such as L-aribinose,D-galactose, acetyl, feruloyl, p-coumaroyl, and glucuronic acidresidues.

The biodegradation of the xylan backbone depends on two classes ofenzymes: endoxylanases and beta-xylosidases. Endoxylanases (EC 3.2.1.8)cleave the xylan backbone into smaller oligosaccharides, which can befurther degraded to xylose by beta-xylosidases (EC 3.2.1.37). Otherenzymes involved in the degradation of xylan include, for example,acetylxylan esterase, arabinase, alpha-glucuronidase, feruloyl esterase,and p-coumaric acid esterase.

Acetylxylan esterase (EC 3.1.1.6) removes the 0-acetyl groups frompositions 2 and/or 3 on the beta-D-xylopyranosyl residues ofacetylxylan. Acetylxylan plays an important role in the hydrolysis ofxylan because the acetyl side groups can interfere sterically with theapproach of enzymes that cleave the backbone. Removal of the acetyl sidegroups facilitates the action of endoxylanases. A classification systemfor carbohydrate esterases, based on sequence similarity, has led to thedefinition of 13 families, seven of which contain acetylxylan esterases(Henrissat B., 1991, Biochem. J. 280: 309-316, and Henrissat andBairoch, 1996, Biochem. J. 316: 695-696).

Margolles-Clark et al., 1996, Eur. J. Biochem. 237: 553-560, disclose anacetylxylan esterase from Trichoderma reesei. Sundberg and Poutanen,1991, Biotechnol. Appl. Biochem. 13: 1-11, disclose the purification andproperties of two acetylxylan esterases of Trichoderma reesei. WO2005/001036 discloses an acetylxylan esterase gene from Trichodermareesei. U.S. Pat. No. 5,681,732 discloses an acetylxylan esterase genefrom Aspergillus niger. U.S. Pat. No. 5,763,260 discloses methods foraltering the properties of acetylated xylan.

The present invention relates to polypeptides having acetylxylanesterase activity and polynucleotides encoding the polypeptides.

SUMMARY OF THE INVENTION

The present invention relates to isolated polypeptides havingacetylxylan esterase activity selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence having at least 75%identity to the mature polypeptide of SEQ ID NO: 2;

(b) a polypeptide encoded by a polynucleotide that hybridizes under atleast medium-high stringency conditions with (i) the mature polypeptidecoding sequence of SEQ ID NO: 1, (ii) the cDNA sequence contained in themature polypeptide coding sequence of SEQ ID NO: 1, or (iii) afull-length complementary strand of (i) or (ii);

(c) a polypeptide encoded by a polynucleotide comprising a nucleotidesequence having at least 75% identity to the mature polypeptide codingsequence of SEQ ID NO: 1; and

(d) a variant comprising a substitution, deletion, and/or insertion ofone or more (several) amino acids of the mature polypeptide of SEQ IDNO: 2.

The present invention also relates to isolated polynucleotides encodingpolypeptides having acetylxylan esterase activity, selected from thegroup consisting of:

(a) a polynucleotide encoding a polypeptide comprising an amino acidsequence having at least 75% identity to the mature polypeptide of SEQID NO: 2;

(b) a polynucleotide that hybridizes under at least medium-highstringency conditions with (i) the mature polypeptide coding sequence ofSEQ ID NO: 1, (ii) the cDNA sequence contained in the mature polypeptidecoding sequence of SEQ ID NO: 1, or (iii) a full-length complementarystrand of (i) or (ii);

(c) a polynucleotide comprising a nucleotide sequence having at least75% identity to the mature polypeptide coding sequence of SEQ ID NO: 1;and

(d) a polynucleotide encoding a variant comprising a substitution,deletion, and/or insertion of one or more (several) amino acids of themature polypeptide of SEQ ID NO: 2.

The present invention also relates to nucleic acid constructs,recombinant expression vectors, recombinant host cells comprising thepolynucleotides, and methods of producing a polypeptide havingacetylxylan esterase activity.

The present invention also relates to methods of inhibiting theexpression of a polypeptide having acetylxylan esterase activity in acell, comprising administering to the cell or expressing in the cell adouble-stranded RNA (dsRNA) molecule, wherein the dsRNA comprises asubsequence of a polynucleotide of the present invention. The presentalso relates to a double-stranded inhibitory RNA (dsRNA) molecule,wherein optionally the dsRNA is a siRNA or a miRNA molecule.

The present invention also relates to methods for degrading axylan-containing material with a polypeptide having acetylxylan esteraseactivity.

The present invention also relates to plants comprising an isolatedpolynucleotide encoding a polypeptide having acetylxylan esteraseactivity.

The present invention also relates to methods of producing a polypeptidehaving acetylxylan esterase, comprising: (a) cultivating a transgenicplant or a plant cell comprising a polynucleotide encoding thepolypeptide having acetylxylan esterase activity under conditionsconducive for production of the polypeptide; and (b) recovering thepolypeptide.

The present invention further relates to nucleic acid constructscomprising a gene encoding a protein, wherein the gene is operablylinked to a nucleotide sequence encoding a signal peptide comprising orconsisting of amino acids 1 to 19 of SEQ ID NO: 2, wherein the gene isforeign to the nucleotide sequence.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A and 1B show the genomic DNA sequence and the deduced amino acidsequence of a Humicola insolens DSM 1800 CE1 acetylxylan esterase (SEQID NOs: 1 and 2, respectively). Predicted intronic sequences areunderlined in bold.

FIG. 2 shows a restriction map of pMMar6.

FIG. 3 shows a restriction map of pHinsAXE2.

DEFINITIONS

Acetylxylan esterase activity: The term “acetylxylan esterase activity”is defined herein as a carboxylesterase activity (EC 3.1.1.72) thatcatalyses the hydrolysis of acetyl groups from polymeric xylan,acetylated xylose, acetylated glucose, alpha-napthyl acetate, andp-nitrophenyl acetate. For purposes of the present invention,acetylxylan esterase activity is determined according to the proceduredescribed herein in the Examples. One unit of acetylxylan esteraseactivity is defined as the amount of enzyme capable of releasing 1 μmoleof p-nitrophenolate anion per minute at pH 5, 25° C.

The polypeptides of the present invention have at least 20%, preferablyat least 40%, more preferably at least 50%, more preferably at least60%, more preferably at least 70%, more preferably at least 80%, evenmore preferably at least 90%, most preferably at least 95%, and evenmost preferably at least 100% of the acetylxylan esterase activity ofthe mature polypeptide of SEQ ID NO: 2.

Family CE1 or CE1: The term “Family CE1” or “CE1” is defined herein as apolypeptide falling into the carbohydrate esterase Family according toCoutinho and Henrissat, (1999) Carbohydrate-active enzymes: anintegrated database approach. In “Recent Advances in CarbohydrateBioengineering”, H. J. Gilbert, G. Davies, B. Henrissat and B. Svenssoneds., The Royal Society of Chemistry, Cambridge, pp. 3-12.

Xylan-containing material: The term “xylan-containing material” isdefined herein as any material comprising xylan as a constituent. Xylanis a plant cell wall polysaccharide containing a backbone ofbeta-1,4-linked xylose residues. Side chains of 4-O-methylglucuronicacid and arabinose are generally present in varying amounts, togetherwith acetyl and feruloyl groups. Xylan is a major constituent ofhemicellulose.

Isolated polypeptide: The term “isolated polypeptide” as used hereinrefers to a polypeptide that is isolated from a source. In a preferredaspect, the polypeptide is at least 1% pure, preferably at least 5%pure, more preferably at least 10% pure, more preferably at least 20%pure, more preferably at least 40% pure, more preferably at least 60%pure, even more preferably at least 80% pure, and most preferably atleast 90% pure, as determined by SDS-PAGE.

Substantially pure polypeptide: The term “substantially purepolypeptide” denotes herein a polypeptide preparation that contains atmost 10%, preferably at most 8%, more preferably at most 6%, morepreferably at most 5%, more preferably at most 4%, more preferably atmost 3%, even more preferably at most 2%, most preferably at most 1%,and even most preferably at most 0.5% by weight of other polypeptidematerial with which it is natively or recombinantly associated. It is,therefore, preferred that the substantially pure polypeptide is at least92% pure, preferably at least 94% pure, more preferably at least 95%pure, more preferably at least 96% pure, more preferably at least 97%pure, more preferably at least 98% pure, even more preferably at least99% pure, most preferably at least 99.5% pure, and even most preferably100% pure by weight of the total polypeptide material present in thepreparation. The polypeptides of the present invention are preferably ina substantially pure form, i.e., that the polypeptide preparation isessentially free of other polypeptide material with which it is nativelyor recombinantly associated. This can be accomplished, for example, bypreparing the polypeptide by well-known recombinant methods or byclassical purification methods.

Mature polypeptide: The term “mature polypeptide” is defined herein as apolypeptide having acetylxylan esterase activity in its final formfollowing translation and any post-translational modifications, such asN-terminal processing, C-terminal truncation, glycosylation,phosphorylation, etc. In a preferred aspect, the mature polypeptide isamino acids 20 to 377 of SEQ ID NO: 2 based on the SignalP program(Nielsen et al., 1997, Protein Engineering 10: 1-6) that predicts aminoacids 1 to 19 of SEQ ID NO: 2 are a signal peptide.

Mature polypeptide coding sequence: The term “mature polypeptide codingsequence” is defined herein as a nucleotide sequence that encodes amature polypeptide having acetylxylan esterase activity. In a preferredaspect, the mature polypeptide coding sequence is nucleotides 58 to 1266of SEQ ID NO: 1 based on the SignalP program (Nielsen et al., 1997,supra) that predicts nucleotides 1 to 57 of SEQ ID NO: 1 encode a signalpeptide.

Identity: The relatedness between two amino acid sequences or betweentwo nucleotide sequences is described by the parameter “identity”.

For purposes of the present invention, the degree of identity betweentwo amino acid sequences is determined using the Needleman-Wunschalgorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) asimplemented in the Needle program of the EMBOSS package (EMBOSS: TheEuropean Molecular Biology Open Software Suite, Rice et al., 2000,Trends in Genetics 16: 276-277), preferably version 3.0.0 or later. Theoptional parameters used are gap open penalty of 10, gap extensionpenalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62)substitution matrix. The output of Needle labeled “longest identity”(obtained using the —nobrief option) is used as the percent identity andis calculated as follows:

(Identical Residues×100)/(Length of Alignment−Total Number of Gaps inAlignment)

For purposes of the present invention, the degree of identity betweentwo deoxyribonucleotide sequences is determined using theNeedleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) asimplemented in the Needle program of the EMBOSS package (EMBOSS: TheEuropean Molecular Biology Open Software Suite, Rice et al., 2000,supra), preferably version 3.0.0 or later. The optional parameters usedare gap open penalty of 10, gap extension penalty of 0.5, and theEDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The outputof Needle labeled “longest identity” (obtained using the—nobrief option)is used as the percent identity and is calculated as follows:

(Identical Deoxyribonucleotides×100)/(Length of Alignment−Total Numberof Gaps in Alignment)

Homologous sequence: The term “homologous sequence” is defined herein asa predicted protein that has an E value (or expectancy score) of lessthan 0.001 in a tfasty search (Pearson, W. R., 1999, in BioinformaticsMethods and Protocols, S. Misener and S. A. Krawetz, ed., pp. 185-219)with the Humicola insolens acetylxylan esterase of SEQ ID NO: 2 or themature polypeptide thereof.

Polypeptide fragment: The term “polypeptide fragment” is defined hereinas a polypeptide having one or more (several) amino acids deleted fromthe amino and/or carboxyl terminus of the mature polypeptide of SEQ IDNO: 2; or a homologous sequence thereof; wherein the fragment hasacetylxylan esterase activity. In a preferred aspect, a fragmentcontains at least 310 amino acid residues, more preferably at least 325amino acid residues, and most preferably at least 340 amino acidresidues, of the mature polypeptide of SEQ ID NO: 2 or a homologoussequence thereof.

Subsequence: The term “subsequence” is defined herein as a nucleotidesequence having one or more (several) nucleotides deleted from the 5′and/or 3′ end of the mature polypeptide coding sequence of SEQ ID NO: 1;or a homologous sequence thereof; wherein the subsequence encodes apolypeptide fragment having acetylxylan esterase activity. In apreferred aspect, a subsequence contains at least 930 nucleotides, morepreferably at least 975 nucleotides, and most preferably at least 1020nucleotides of the mature polypeptide coding sequence of SEQ ID NO: 1 ora homologous sequence thereof.

Allelic variant: The term “allelic variant” denotes herein any of two ormore alternative forms of a gene occupying the same chromosomal locus.Allelic variation arises naturally through mutation, and may result inpolymorphism within populations. Gene mutations can be silent (no changein the encoded polypeptide) or may encode polypeptides having alteredamino acid sequences. An allelic variant of a polypeptide is apolypeptide encoded by an allelic variant of a gene.

Isolated polynucleotide: The term “isolated polynucleotide” as usedherein refers to a polynucleotide that is isolated from a source. In apreferred aspect, the polynucleotide is at least 1% pure, preferably atleast 5% pure, more preferably at least 10% pure, more preferably atleast 20% pure, more preferably at least 40% pure, more preferably atleast 60% pure, even more preferably at least 80% pure, and mostpreferably at least 90% pure, as determined by agarose electrophoresis.

Substantially pure polynucleotide: The term “substantially purepolynucleotide” as used herein refers to a polynucleotide preparationfree of other extraneous or unwanted nucleotides and in a form suitablefor use within genetically engineered protein production systems. Thus,a substantially pure polynucleotide contains at most 10%, preferably atmost 8%, more preferably at most 6%, more preferably at most 5%, morepreferably at most 4%, more preferably at most 3%, even more preferablyat most 2%, most preferably at most 1%, and even most preferably at most0.5% by weight of other polynucleotide material with which it isnatively or recombinantly associated. A substantially purepolynucleotide may, however, include naturally occurring 5′ and 3′untranslated regions, such as promoters and terminators. It is preferredthat the substantially pure polynucleotide is at least 90% pure,preferably at least 92% pure, more preferably at least 94% pure, morepreferably at least 95% pure, more preferably at least 96% pure, morepreferably at least 97% pure, even more preferably at least 98% pure,most preferably at least 99% pure, and even most preferably at least99.5% pure by weight. The polynucleotides of the present invention arepreferably in a substantially pure form, i.e., that the polynucleotidepreparation is essentially free of other polynucleotide material withwhich it is natively or recombinantly associated. The polynucleotidesmay be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or anycombinations thereof.

Coding sequence: When used herein the term “coding sequence” means anucleotide sequence, which directly specifies the amino acid sequence ofits protein product. The boundaries of the coding sequence are generallydetermined by an open reading frame, which usually begins with the ATGstart codon or alternative start codons such as GTG and TTG and endswith a stop codon such as TAA, TAG, and TGA. The coding sequence may bea DNA, cDNA, synthetic, or recombinant nucleotide sequence.

cDNA: The term “cDNA” is defined herein as a DNA molecule that can beprepared by reverse transcription from a mature, spliced, mRNA moleculeobtained from a eukaryotic cell. cDNA lacks intron sequences that may bepresent in the corresponding genomic DNA. The initial, primary RNAtranscript is a precursor to mRNA that is processed through a series ofsteps before appearing as mature spliced mRNA. These steps include theremoval of intron sequences by a process called splicing. cDNA derivedfrom mRNA lacks, therefore, any intron sequences.

Nucleic acid construct: The term “nucleic acid construct” as used hereinrefers to a nucleic acid molecule, either single- or double-stranded,which is isolated from a naturally occurring gene or which is modifiedto contain segments of nucleic acids in a manner that would nototherwise exist in nature or which is synthetic. The term nucleic acidconstruct is synonymous with the term “expression cassette” when thenucleic acid construct contains the control sequences required forexpression of a coding sequence of the present invention.

Control sequences: The term “control sequences” is defined herein toinclude all components necessary for the expression of a polynucleotideencoding a polypeptide of the present invention. Each control sequencemay be native or foreign to the nucleotide sequence encoding thepolypeptide or native or foreign to each other. Such control sequencesinclude, but are not limited to, a leader, polyadenylation sequence,propeptide sequence, promoter, signal peptide sequence, andtranscription terminator. At a minimum, the control sequences include apromoter, and transcriptional and translational stop signals. Thecontrol sequences may be provided with linkers for the purpose ofintroducing specific restriction sites facilitating ligation of thecontrol sequences with the coding region of the nucleotide sequenceencoding a polypeptide.

Operably linked: The term “operably linked” denotes herein aconfiguration in which a control sequence is placed at an appropriateposition relative to the coding sequence of the polynucleotide sequencesuch that the control sequence directs the expression of the codingsequence of a polypeptide.

Expression: The term “expression” includes any step involved in theproduction of the polypeptide including, but not limited to,transcription, post-transcriptional modification, translation,post-translational modification, and secretion.

Expression vector: The term “expression vector” is defined herein as alinear or circular DNA molecule that comprises a polynucleotide encodinga polypeptide of the present invention and is operably linked toadditional nucleotides that provide for its expression.

Host cell: The term “host cell”, as used herein, includes any cell typethat is susceptible to transformation, transfection, transduction, andthe like with a nucleic acid construct or expression vector comprising apolynucleotide of the present invention.

Modification: The term “modification” means herein any chemicalmodification of the polypeptide consisting of the mature polypeptide ofSEQ ID NO: 2; or a homologous sequence thereof; as well as geneticmanipulation of the DNA encoding such a polypeptide. The modificationcan be a substitution, a deletion, and/or an insertion of one or more(several) amino acids as well as replacements of one or more (several)amino acid side chains.

Artificial variant: When used herein, the term “artificial variant”means a polypeptide having acetylxylan esterase activity produced by anorganism expressing a modified polynucleotide sequence of the maturepolypeptide coding sequence of SEQ ID NO: 1; or a homologous sequencethereof. The modified nucleotide sequence is obtained through humanintervention by modification of the polynucleotide sequence disclosed inSEQ ID NO: 1; or a homologous sequence thereof.

DETAILED DESCRIPTION OF THE INVENTION

Polypeptides having Acetylxylan Esterase Activity

In a first aspect, the present invention relates to isolatedpolypeptides comprising an amino acid sequence having a degree ofidentity to the mature polypeptide of SEQ ID NO: 2 of preferably atleast 75%, more preferably at least 80%, more preferably at least 85%,even more preferably at least 90%, most preferably at least 95%, andeven most preferably at least 96%, at least 97%, at least 98%, or atleast 99%, which have acetylxylan esterase activity (hereinafter“homologous polypeptides”). In a preferred aspect, the homologouspolypeptides have an amino acid sequence that differs by ten aminoacids, preferably by five amino acids, more preferably by four aminoacids, even more preferably by three amino acids, most preferably by twoamino acids, and even most preferably by one amino acid from the maturepolypeptide of SEQ ID NO: 2.

A polypeptide of the present invention preferably comprises the aminoacid sequence of SEQ ID NO: 2 or an allelic variant thereof; or afragment thereof having acetylxylan esterase activity. In a preferredaspect, the polypeptide comprises the amino acid sequence of SEQ ID NO:2. In another preferred aspect, the polypeptide comprises the maturepolypeptide of SEQ ID NO: 2. In another preferred aspect, thepolypeptide comprises amino acids 20 to 377 of SEQ ID NO: 2, or anallelic variant thereof; or a fragment thereof having acetylxylanesterase activity. In another preferred aspect, the polypeptidecomprises amino acids 20 to 377 of SEQ ID NO: 2. In another preferredaspect, the polypeptide consists of the amino acid sequence of SEQ IDNO: 2 or an allelic variant thereof; or a fragment thereof havingacetylxylan esterase activity. In another preferred aspect, thepolypeptide consists of the amino acid sequence of SEQ ID NO: 2. Inanother preferred aspect, the polypeptide consists of the maturepolypeptide of SEQ ID NO: 2. In another preferred aspect, thepolypeptide consists of amino acids 20 to 377 of SEQ ID NO: 2 or anallelic variant thereof; or a fragment thereof having acetylxylanesterase activity. In another preferred aspect, the polypeptide consistsof amino acids 20 to 377 of SEQ ID NO: 2.

In a second aspect, the present invention relates to isolatedpolypeptides having acetylxylan esterase activity that are encoded bypolynucleotides that hybridize under preferably very low stringencyconditions, more preferably low stringency conditions, more preferablymedium stringency conditions, more preferably medium-high stringencyconditions, even more preferably high stringency conditions, and mostpreferably very high stringency conditions with (i) the maturepolypeptide coding sequence of SEQ ID NO: 1, (ii) the cDNA sequencecontained in the mature polypeptide coding sequence of SEQ ID NO: 1,(iii) a subsequence of (i) or (ii), or (iv) a full-length complementarystrand of (i), (ii), or (iii) (J. Sambrook, E. F. Fritsch, and T.Maniatis, 1989, Molecular Cloning, A Laboratory Manual, 2d edition, ColdSpring Harbor, N.Y.). A subsequence of the mature polypeptide codingsequence of SEQ ID NO: 1 contains at least 100 contiguous nucleotides orpreferably at least 200 contiguous nucleotides. Moreover, thesubsequence may encode a polypeptide fragment having acetylxylanesterase activity. In a preferred aspect, the complementary strand isthe full-length complementary strand of the mature polypeptide codingsequence of SEQ ID NO: 1.

The nucleotide sequence of SEQ ID NO: 1; or a subsequence thereof; aswell as the amino acid sequence of SEQ ID NO: 2; or a fragment thereof;may be used to design nucleic acid probes to identify and clone DNAencoding polypeptides having acetylxylan esterase activity from strainsof different genera or species according to methods well known in theart. In particular, such probes can be used for hybridization with thegenomic or cDNA of the genus or species of interest, following standardSouthern blotting procedures, in order to identify and isolate thecorresponding gene therein. Such probes can be considerably shorter thanthe entire sequence, but should be at least 14, preferably at least 25,more preferably at least 35, and most preferably at least 70 nucleotidesin length. It is, however, preferred that the nucleic acid probe is atleast 100 nucleotides in length. For example, the nucleic acid probe maybe at least 200 nucleotides, preferably at least 300 nucleotides, morepreferably at least 400 nucleotides, or most preferably at least 500nucleotides in length. Even longer probes may be used, e.g., nucleicacid probes that are preferably at least 600 nucleotides, morepreferably at least 700 nucleotides, even more preferably at least 800nucleotides, or most preferably at least 900 nucleotides in length. BothDNA and RNA probes can be used. The probes are typically labeled fordetecting the corresponding gene (for example, with ³²P, ³H, ³⁵5,biotin, or avidin). Such probes are encompassed by the presentinvention.

A genomic DNA or cDNA library prepared from such other strains may,therefore, be screened for DNA that hybridizes with the probes describedabove and encodes a polypeptide having acetylxylan esterase activity.Genomic or other DNA from such other strains may be separated by agaroseor polyacrylamide gel electrophoresis, or other separation techniques.DNA from the libraries or the separated DNA may be transferred to andimmobilized on nitrocellulose or other suitable carrier material. Inorder to identify a clone or DNA that is homologous with SEQ ID NO: 1;or a subsequence thereof; the carrier material is preferably used in aSouthern blot.

For purposes of the present invention, hybridization indicates that thenucleotide sequence hybridizes to a labeled nucleic acid probecorresponding to the mature polypeptide coding sequence of SEQ ID NO: 1;the cDNA sequence contained in the mature polypeptide coding sequence ofSEQ ID NO: 1; its full-length complementary strand; or a subsequencethereof; under very low to very high stringency conditions. Molecules towhich the nucleic acid probe hybridizes under these conditions can bedetected using, for example, X-ray film.

In a preferred aspect, the nucleic acid probe is the mature polypeptidecoding sequence of SEQ ID NO: 1. In another preferred aspect, thenucleic acid probe is nucleotides 58 to 1266 of SEQ ID NO: 1. In anotherpreferred aspect, the nucleic acid probe is a polynucleotide sequencethat encodes the polypeptide of SEQ ID NO: 2, or a subsequence thereof.In another preferred aspect, the nucleic acid probe is SEQ ID NO: 1. Inanother preferred aspect, the nucleic acid probe is the polynucleotidesequence contained in plasmid pHinsAXE2 which is contained in E. coliNRRL B-50076, wherein the polynucleotide sequence thereof encodes apolypeptide having acetylxylan esterase activity. In another preferredaspect, the nucleic acid probe is the mature polypeptide coding regioncontained in plasmid pHinsAXE2 which is contained in E. coli NRRLB-50076.

For long probes of at least 100 nucleotides in length, very low to veryhigh stringency conditions are defined as prehybridization andhybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 μg/ml sheared anddenatured salmon sperm DNA, and either 25% formamide for very low andlow stringencies, 35% formamide for medium and medium-high stringencies,or 50% formamide for high and very high stringencies, following standardSouthern blotting procedures for 12 to 24 hours optimally.

For long probes of at least 100 nucleotides in length, the carriermaterial is finally washed three times each for 15 minutes using 2×SSC,0.2% SDS preferably at 45° C. (very low stringency), more preferably at50° C. (low stringency), more preferably at 55° C. (medium stringency),more preferably at 60° C. (medium-high stringency), even more preferablyat 65° C. (high stringency), and most preferably at 70° C. (very highstringency).

For short probes of about 15 nucleotides to about 70 nucleotides inlength, stringency conditions are defined as prehybridization,hybridization, and washing post-hybridization at about 5° C. to about10° C. below the calculated T_(m) using the calculation according toBolton and McCarthy (1962, Proceedings of the National Academy ofSciences USA 48:1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6 mM EDTA,0.5% NP-40, 1× Denhardt's solution, 1 mM sodium pyrophosphate, 1 mMsodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per mlfollowing standard Southern blotting procedures for 12 to 24 hoursoptimally.

For short probes of about 15 nucleotides to about 70 nucleotides inlength, the carrier material is washed once in 6×SCC plus 0.1% SDS for15 minutes and twice each for 15 minutes using 6×SSC at 5° C. to 10° C.below the calculated T_(m).

In a third aspect, the present invention relates to isolatedpolypeptides having acetylxylan esterase activity encoded bypolynucleotides comprising or consisting of nucleotide sequences thathave a degree of identity to the mature polypeptide coding sequence ofSEQ ID NO: 1 of preferably at least 60%, more preferably at least 65%,more preferably at least 70%, more preferably at least 75%, morepreferably at least 80%, more preferably at least 85%, even morepreferably at least 90%, most preferably at least 95%, and even mostpreferably at least 96%, at least 97%, at least 98%, or at least 99%,which encode a polypeptide having acetylxylan esterase activity. Seepolynucleotide section herein.

In a fourth aspect, the present invention relates to artificial variantscomprising a substitution, deletion, and/or insertion of one or more (orseveral) amino acids of the mature polypeptide of SEQ ID NO: 2; or ahomologous sequence thereof. Preferably, amino acid changes are of aminor nature, that is conservative amino acid substitutions orinsertions that do not significantly affect the folding and/or activityof the protein; small deletions, typically of one to about 30 aminoacids; small amino- or carboxyl-terminal extensions, such as anamino-terminal methionine residue; a small linker peptide of up to about20-25 residues; or a small extension that facilitates purification bychanging net charge or another function, such as a poly-histidine tract,an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the group of basicamino acids (arginine, lysine and histidine), acidic amino acids(glutamic acid and aspartic acid), polar amino acids (glutamine andasparagine), hydrophobic amino acids (leucine, isoleucine and valine),aromatic amino acids (phenylalanine, tryptophan and tyrosine), and smallamino acids (glycine, alanine, serine, threonine and methionine). Aminoacid substitutions that do not generally alter specific activity areknown in the art and are described, for example, by H. Neurath and R. L.Hill, 1979, In, The Proteins, Academic Press, New York. The mostcommonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser,Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg,Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly.

In addition to the 20 standard amino acids, non-standard amino acids(such as 4-hydroxyproline, 6-N-methyl lysine, 2-aminoisobutyric acid,isovaline, and alpha-methyl serine) may be substituted for amino acidresidues of a wild-type polypeptide. A limited number ofnon-conservative amino acids, amino acids that are not encoded by thegenetic code, and unnatural amino acids may be substituted for aminoacid residues. “Unnatural amino acids” have been modified after proteinsynthesis, and/or have a chemical structure in their side chain(s)different from that of the standard amino acids. Unnatural amino acidscan be chemically synthesized, and preferably, are commerciallyavailable, and include pipecolic acid, thiazolidine carboxylic acid,dehydroproline, 3- and 4-methylproline, and 3,3-dimethylproline.

Alternatively, the amino acid changes are of such a nature that thephysico-chemical properties of the polypeptides are altered. Forexample, amino acid changes may improve the thermal stability of thepolypeptide, alter the substrate specificity, change the pH optimum, andthe like.

Essential amino acids in the parent polypeptide can be identifiedaccording to procedures known in the art, such as site-directedmutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, 1989,Science 244: 1081-1085). In the latter technique, single alaninemutations are introduced at every residue in the molecule, and theresultant mutant molecules are tested for biological activity (i.e.,acetylxylan esterase activity) to identify amino acid residues that arecritical to the activity of the molecule. See also, Hilton et al., 1996,J. Biol. Chem. 271: 4699-4708. The active site of the enzyme or otherbiological interaction can also be determined by physical analysis ofstructure, as determined by such techniques as nuclear magneticresonance, crystallography, electron diffraction, or photoaffinitylabeling, in conjunction with mutation of putative contact site aminoacids. See, for example, de Vos et al., 1992, Science 255: 306-312;Smith et al., 1992, J. Mol. Biol. 224: 899-904; Wlodaver et al., 1992,FEBS Lett. 309: 59-64. The identities of essential amino acids can alsobe inferred from analysis of identities with polypeptides that arerelated to a polypeptide according to the invention.

Single or multiple amino acid substitutions, deletions, and/orinsertions can be made and tested using known methods of mutagenesis,recombination, and/or shuffling, followed by a relevant screeningprocedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988,Science 241: 53-57; Bowie and Sauer, 1989, Proc. Natl. Acad. Sci. USA86: 2152-2156; WO 95/17413; or WO 95/22625. Other methods that can beused include error-prone PCR, phage display (e.g., Lowman et al., 1991,Biochem. 30: 10832-10837; U.S. Pat. No. 5,223,409; WO 92/06204), andregion-directed mutagenesis (Derbyshire et al., 1986, Gene 46: 145; Neret al., 1988, DNA 7: 127).

Mutagenesis/shuffling methods can be combined with high-throughput,automated screening methods to detect activity of cloned, mutagenizedpolypeptides expressed by host cells (Ness et al., 1999, NatureBiotechnology 17: 893-896). Mutagenized DNA molecules that encode activepolypeptides can be recovered from the host cells and rapidly sequencedusing standard methods in the art. These methods allow the rapiddetermination of the importance of individual amino acid residues in apolypeptide of interest, and can be applied to polypeptides of unknownstructure.

The total number of amino acid substitutions, deletions and/orinsertions of the mature polypeptide of SEQ ID NO: 2, such as aminoacids 20 to 377 of SEQ ID NO: 2, is 10, preferably 9, more preferably 8,more preferably 7, more preferably at most 6, more preferably 5, morepreferably 4, even more preferably 3, most preferably 2, and even mostpreferably 1.

Sources of Polypeptides having Acetylxylan Esterase Activity

A polypeptide of the present invention may be obtained frommicroorganisms of any genus. For purposes of the present invention, theterm “obtained from” as used herein in connection with a given sourceshall mean that the polypeptide encoded by a nucleotide sequence isproduced by the source or by a strain in which the nucleotide sequencefrom the source has been inserted. In a preferred aspect, thepolypeptide obtained from a given source is secreted extracellularly.

A polypeptide having acetylxylan esterase activity of the presentinvention may be a bacterial polypeptide. For example, the polypeptidemay be a gram positive bacterial polypeptide such as a Bacillus,Streptococcus, Streptomyces, Staphylococcus, Enterococcus,Lactobacillus, Lactococcus, Clostridium, Geobacillus, or Oceanobacilluspolypeptide having acetylxylan esterase activity, or a Gram negativebacterial polypeptide such as an E. coli, Pseudomonas, Salmonella,Campylobacter, Helicobacter, Flavobacterium, Fusobacterium, Ilyobacter,Neisseria, or Ureaplasma polypeptide having acetylxylan esteraseactivity.

In a preferred aspect, the polypeptide is a Bacillus alkalophilus,Bacillus amyloliquefaciens, Bacillus brevis, Bacillus circulans,Bacillus clausii, Bacillus coagulans, Bacillus firmus, Bacillus lautus,Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacilluspumilus, Bacillus stearothermophilus, Bacillus subtilis, or Bacillusthuringiensis polypeptide having acetylxylan esterase activity.

In another preferred aspect, the polypeptide is a Streptococcusequisimilis, Streptococcus pyogenes, Streptococcus uberis, orStreptococcus equi subsp. Zooepidemicus polypeptide having acetylxylanesterase activity.

In another preferred aspect, the polypeptide is a Streptomycesachromogenes, Streptomyces avermitilis, Streptomyces coelicolor,Streptomyces griseus, or Streptomyces lividans polypeptide havingacetylxylan esterase activity.

A polypeptide having acetylxylan esterase activity of the presentinvention may also be a fungal polypeptide, and more preferably a yeastpolypeptide such as a Candida, Kluyveromyces, Pichia, Saccharomyces,Schizosaccharomyces, or Yarrowia polypeptide having acetylxylan esteraseactivity; or more preferably a filamentous fungal polypeptide such as anAcremonium, Agaricus, Alternaria, Aspergillus, Aureobasidium,Botryospaeria, Ceriporiopsis, Chaetomidium, Chrysosporium, Claviceps,Cochliobolus, Coprinopsis, Coptotermes, Corynascus, Cryphonectria,Cryptococcus, Diplodia, Exidia, Filibasidium, Fusarium, Gibberella,Holomastigotoides, Humicola, Irpex, Lentinula, Leptospaeria,Magnaporthe, Melanocarpus, Meripilus, Mucor, Myceliophthora,Neocallimastix, Neurospora, Paecilomyces, Penicillium, Phanerochaete,Piromyces, Poitrasia, Pseudoplectania, Pseudotrichonympha, Rhizomucor,Schizophyllum, Scytalidium, Talaromyces, Thermoascus, Thielavia,Tolypocladium, Trichoderma, Trichophaea, Verticillium, Volvariella, orXylaria polypeptide having acetylxylan esterase activity.

In a preferred aspect, the polypeptide is a Saccharomycescarlsbergensis, Saccharomyces cerevisiae, Saccharomyces diastaticus,Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomycesnorbensis, or Saccharomyces oviformis polypeptide having acetylxylanesterase activity.

In another preferred aspect, the polypeptide is an Acremoniumcellulolyticus, Aspergillus aculeatus, Aspergillus awamori, Aspergillusfumigatus, Aspergillus foetidus, Aspergillus japonicus, Aspergillusnidulans, Aspergillus niger, Aspergillus oryzae, Chrysosporiumkeratinophilum, Chrysosporium lucknowense, Chrysosporium tropicum,Chrysosporium merdarium, Chrysosporium inops, Chrysosporium pannicola,Chrysosporium queenslandicum, Chrysosporium zonatum, Fusariumbactridioides, Fusarium cerealis, Fusarium crookwellense, Fusariumculmorum, Fusarium graminearum, Fusarium graminum, Fusariumheterosporum, Fusarium negundi, Fusarium oxysporum, Fusariumreticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum,Fusarium sporotrichioides, Fusarium sulphureum, Fusarium torulosum,Fusarium trichothecioides, Fusarium venenatum, Irpex lacteus, Mucormiehei, Myceliophthora thermophila, Neurospora crassa, Penicilliumfuniculosum, Penicillium purpurogenum, Phanerochaete chtysosporium,Thielavia achromatica, Thielavia albomyces, Thielavia albopilosa,Thielavia australeinsis, Thielavia fimeti, Thielavia microspora,Thielavia ovispora, Thielavia peruviana, Thielavia spededonium,Thielavia setosa, Thielavia subthermophila, Thielavia terrestris,Trichoderma harzianum, Trichoderma koningii, Trichodermalongibrachiatum, Trichoderma reesei, or Trichoderma viride polypeptidehaving acetylxylan esterase activity.

In another preferred aspect, the polypeptide is a Humicola grisea,Humicola insolens, or Humicola lanuginosa polypeptide having acetylxylanesterase activity.

In a more preferred aspect, the polypeptide is a Humicola insolenspolypeptide having acetylxylan esterase activity. In a most preferredaspect, the polypeptide is a Humicola insolens DSM 1800 polypeptidehaving acetylxylan esterase activity, e.g., the polypeptide comprisingthe mature polypeptide of SEQ ID NO: 2.

It will be understood that for the aforementioned species the inventionencompasses both the perfect and imperfect states, and other taxonomicequivalents, e.g., anamorphs, regardless of the species name by whichthey are known. Those skilled in the art will readily recognize theidentity of appropriate equivalents.

Strains of these species are readily accessible to the public in anumber of culture collections, such as the American Type CultureCollection (ATCC), Deutsche Sammlung von Mikroorganismen andZellkulturen GmbH (DSM), Centraalbureau Voor Schimmelcultures (CBS), andAgricultural Research Service Patent Culture Collection, NorthernRegional Research Center (NRRL).

Furthermore, such polypeptides may be identified and obtained from othersources including microorganisms isolated from nature (e.g., soil,composts, water, etc.) using the above-mentioned probes. Techniques forisolating microorganisms from natural habitats are well known in theart. The polynucleotide may then be obtained by similarly screening agenomic or cDNA library of such a microorganism. Once a polynucleotidesequence encoding a polypeptide has been detected with the probe(s), thepolynucleotide can be isolated or cloned by utilizing techniques thatare well known to those of ordinary skill in the art (see, e.g.,Sambrook et al., 1989, supra).

Polypeptides of the present invention also include fused polypeptides orcleavable fusion polypeptides in which another polypeptide is fused atthe N-terminus or the C-terminus of the polypeptide or fragment thereof.A fused polypeptide is produced by fusing a nucleotide sequence (or aportion thereof) encoding another polypeptide to a nucleotide sequence(or a portion thereof) of the present invention. Techniques forproducing fusion polypeptides are known in the art, and include ligatingthe coding sequences encoding the polypeptides so that they are in frameand that expression of the fused polypeptide is under control of thesame promoter(s) and terminator.

A fusion polypeptide can further comprise a cleavage site. Uponsecretion of the fusion protein, the site is cleaved releasing thepolypeptide having acetylxylan esterase activity from the fusionprotein. Examples of cleavage sites include, but are not limited to, aKex2 site that encodes the dipeptide Lys-Arg (Martin et al., 2003, J.Ind. Microbiol. Biotechnol. 3: 568-76; Svetina et al., 2000, J.Biotechnol. 76: 245-251; Rasmussen-Wilson et al., 1997, Appl. Environ.Microbiol. 63: 3488-3493; Ward et al., 1995, Biotechnology 13: 498-503;and Contreras et al., 1991, Biotechnology 9: 378-381), an Ile-(Glu orAsp)-Gly-Arg site, which is cleaved by a Factor Xa protease after thearginine residue (Eaton et al., 1986, Biochem. 25: 505-512); aAsp-Asp-Asp-Asp-Lys site, which is cleaved by an enterokinase after thelysine (Collins-Racie et al., 1995, Biotechnology 13: 982-987); aHis-Tyr-Glu site or His-Tyr-Asp site, which is cleaved by Genenase I(Carter et al., 1989, Proteins: Structure, Function, and Genetics 6:240-248); a Leu-Val-Pro-Arg-Gly-Ser site, which is cleaved by thrombinafter the Arg (Stevens, 2003, Drug Discovery World 4: 35-48); aGlu-Asn-Leu-Tyr-Phe-Gln-Gly site, which is cleaved by TEV protease afterthe Gln (Stevens, 2003, supra); and a Leu-Glu-Val-Leu-Phe-Gln-Gly-Prosite, which is cleaved by a genetically engineered form of humanrhinovirus 3C protease after the Gln (Stevens, 2003, supra).

Polynucleotides

The present invention also relates to isolated polynucleotidescomprising or consisting of nucleotide sequences that encodepolypeptides having acetylxylan esterase activity of the presentinvention.

In a preferred aspect, the nucleotide sequence comprises or consists ofSEQ ID NO: 1. In another more preferred aspect, the nucleotide sequencecomprises or consists of the sequence contained in plasmid pHinsAXE2which is contained in E. coli NRRL B-50076. In another preferred aspect,the nucleotide sequence comprises or consists of the mature polypeptidecoding sequence of SEQ ID NO: 1. In another preferred aspect, thenucleotide sequence comprises or consists of nucleotides 58 to 1266 ofSEQ ID NO: 1. In another more preferred aspect, the nucleotide sequencecomprises or consists of the mature polypeptide coding sequencecontained in plasmid pHinsAXE2 which is contained in E. coli NRRLB-50076. The present invention also encompasses nucleotide sequencesthat encode polypeptides comprising or consisting of the amino acidsequence of SEQ ID NO: 2 or the mature polypeptide thereof, which differfrom SEQ ID NO: 1 or the mature polypeptide coding sequence thereof byvirtue of the degeneracy of the genetic code. The present invention alsorelates to subsequences of SEQ ID NO: 1 that encode fragments of SEQ IDNO: 2 that have acetylxylan esterase activity.

The present invention also relates to mutant polynucleotides comprisingor consisting of at least one mutation in the mature polypeptide codingsequence of SEQ ID NO: 1, in which the mutant nucleotide sequenceencodes the mature polypeptide of SEQ ID NO: 2.

The techniques used to isolate or clone a polynucleotide encoding apolypeptide are known in the art and include isolation from genomic DNA,preparation from cDNA, or a combination thereof. The cloning of thepolynucleotides of the present invention from such genomic DNA can beeffected, e.g., by using the well known polymerase chain reaction (PCR)or antibody screening of expression libraries to detect cloned DNAfragments with shared structural features. See, e.g., Innis et al.,1990, PCR: A Guide to Methods and Application, Academic Press, New York.Other nucleic acid amplification procedures such as ligase chainreaction (LCR), ligated activated transcription (LAT) and nucleotidesequence-based amplification (NASBA) may be used. The polynucleotidesmay be cloned from a strain of Humicola, or another or related organismand thus, for example, may be an allelic or species variant of thepolypeptide encoding region of the nucleotide sequence.

The present invention also relates to isolated polynucleotidescomprising or consisting of nucleotide sequences that have a degree ofidentity to the mature polypeptide coding sequence of SEQ ID NO: 1 ofpreferably at least 75%, more preferably at least 80%, more preferablyat least 85%, even more preferably at least 90%, most preferably atleast 95%, and even most preferably at least 96%, at least 97%, at least98%, or at least 99% identity, which encode a polypeptide havingacetylxylan esterase activity.

Modification of a nucleotide sequence encoding a polypeptide of thepresent invention may be necessary for the synthesis of polypeptidessubstantially similar to the polypeptide. The term “substantiallysimilar” to the polypeptide refers to non-naturally occurring forms ofthe polypeptide. These polypeptides may differ in some engineered wayfrom the polypeptide isolated from its native source, e.g., artificialvariants that differ in specific activity, thermostability, pH optimum,or the like. The variant sequence may be constructed on the basis of thenucleotide sequence presented as the mature polypeptide coding sequenceof SEQ ID NO: 1, e.g., a subsequence thereof, and/or by introduction ofnucleotide substitutions that do not give rise to another amino acidsequence of the polypeptide encoded by the nucleotide sequence, butwhich correspond to the codon usage of the host organism intended forproduction of the enzyme, or by introduction of nucleotide substitutionsthat may give rise to a different amino acid sequence. For a generaldescription of nucleotide substitution, see, e.g., Ford et al., 1991,Protein Expression and Purification 2: 95-107.

It will be apparent to those skilled in the art that such substitutionscan be made outside the regions critical to the function of the moleculeand still result in an active polypeptide. Amino acid residues essentialto the activity of the polypeptide encoded by an isolated polynucleotideof the invention, and therefore preferably not subject to substitution,may be identified according to procedures known in the art, such assite-directed mutagenesis or alanine-scanning mutagenesis (see, e.g.,Cunningham and Wells, 1989, supra). In the latter technique, mutationsare introduced at every positively charged residue in the molecule, andthe resultant mutant molecules are tested for acetylxylan esteraseactivity to identify amino acid residues that are critical to theactivity of the molecule. Sites of substrate-enzyme interaction can alsobe determined by analysis of the three-dimensional structure asdetermined by such techniques as nuclear magnetic resonance analysis,crystallography or photoaffinity labeling (see, e.g., de Vos et al.,1992, supra; Smith et al., 1992, supra; Wlodaver et al., 1992, supra).

The present invention also relates to isolated polynucleotides encodingpolypeptides of the present invention, which hybridize under very lowstringency conditions, preferably low stringency conditions, morepreferably medium stringency conditions, more preferably medium-highstringency conditions, even more preferably high stringency conditions,and most preferably very high stringency conditions with (i) the maturepolypeptide coding sequence of SEQ ID NO: 1, (ii) the cDNA sequencecontained in the mature polypeptide coding sequence of SEQ ID NO: 1, or(iii) a full-length complementary strand of (i) or (ii); or allelicvariants and subsequences thereof (Sambrook et al., 1989, supra), asdefined herein. In a preferred aspect, the complementary strand is thefull-length complementary strand of the mature polypeptide codingsequence of SEQ ID NO: 1.

The present invention also relates to isolated polynucleotides obtainedby (a) hybridizing a population of DNA under very low, low, medium,medium-high, high, or very high stringency conditions with (i) themature polypeptide coding sequence of SEQ ID NO: 1, (ii) the cDNAsequence contained in the mature polypeptide coding sequence of SEQ IDNO: 1, or (iii) a full-length complementary strand of (i) or (ii); and(b) isolating the hybridizing polynucleotide, which encodes apolypeptide having acetylxylan esterase activity. In a preferred aspect,the complementary strand is the full-length complementary strand of themature polypeptide coding sequence of SEQ ID NO: 1.

Nucleic Acid Constructs

The present invention also relates to nucleic acid constructs comprisingan isolated polynucleotide of the present invention operably linked toone or more (several) control sequences that direct the expression ofthe coding sequence in a suitable host cell under conditions compatiblewith the control sequences.

An isolated polynucleotide encoding a polypeptide of the presentinvention may be manipulated in a variety of ways to provide forexpression of the polypeptide. Manipulation of the polynucleotide'ssequence prior to its insertion into a vector may be desirable ornecessary depending on the expression vector. The techniques formodifying polynucleotide sequences utilizing recombinant DNA methods arewell known in the art.

The control sequence may be an appropriate promoter sequence, anucleotide sequence that is recognized by a host cell for expression ofa polynucleotide encoding a polypeptide of the present invention. Thepromoter sequence contains transcriptional control sequences thatmediate the expression of the polypeptide. The promoter may be anynucleotide sequence that shows transcriptional activity in the host cellof choice including mutant, truncated, and hybrid promoters, and may beobtained from genes encoding extracellular or intracellular polypeptideseither homologous or heterologous to the host cell.

Examples of suitable promoters for directing the transcription of thenucleic acid constructs of the present invention, especially in abacterial host cell, are the promoters obtained from the E. coli lacoperon, Streptomyces coelicolor agarase gene (dagA), Bacillus subtilislevansucrase gene (sacB), Bacillus licheniformis alpha-amylase gene(amyL), Bacillus stearothermophilus maltogenic amylase gene (amyM),Bacillus amyloliquefaciens alpha-amylase gene (amyQ), Bacilluslicheniformis penicillinase gene (penP), Bacillus subtilis xylA and xylBgenes, and prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978,Proceedings of the National Academy of Sciences USA 75: 3727-3731), aswell as the tac promoter (DeBoer et al., 1983, Proceedings of theNational Academy of Sciences USA 80: 21-25). Further promoters aredescribed in “Useful proteins from recombinant bacteria” in ScientificAmerican, 1980, 242: 74-94; and in Sambrook et al., 1989, supra.

Examples of suitable promoters for directing the transcription of thenucleic acid constructs of the present invention in a filamentous fungalhost cell are promoters obtained from the genes for Aspergillus oryzaeTAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus nigerneutral alpha-amylase, Aspergillus niger acid stable alpha-amylase,Aspergillus niger or Aspergillus awamori glucoamylase (glaA), Rhizomucormiehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzaetriose phosphate isomerase, Aspergillus nidulans acetamidase, Fusariumvenenatum amyloglucosidase (WO 00/56900), Fusarium venenatum Daria (WO00/56900), Fusarium venenatum Quinn (WO 00/56900), Fusarium oxysporumtrypsin-like protease (WO 96/00787), Trichoderma reeseibeta-glucosidase, Trichoderma reesei cellobiohydrolase I, Trichodermareesei cellobiohydrolase II, Trichoderma reesei endoglucanase I,Trichoderma reesei endoglucanase II, Trichoderma reesei endoglucanaseIII, Trichoderma reesei endoglucanase IV, Trichoderma reeseiendoglucanase V, Trichoderma reesei xylanase I, Trichoderma reeseixylanase II, Trichoderma reesei beta-xylosidase, as well as the NA2-tpipromoter (a hybrid of the promoters from the genes for Aspergillus nigerneutral alpha-amylase and Aspergillus oryzae triose phosphateisomerase); and mutant, truncated, and hybrid promoters thereof.

In a yeast host, useful promoters are obtained from the genes forSaccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiaegalactokinase (GAL1), Saccharomyces cerevisiae alcoholdehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH1, ADH2/GAP),Saccharomyces cerevisiae triose phosphate isomerase (TPI), Saccharomycescerevisiae metallothionein (CUP1), and Saccharomyces cerevisiae3-phosphoglycerate kinase. Other useful promoters for yeast host cellsare described by Romanos et al., 1992, Yeast 8: 423-488.

The control sequence may also be a suitable transcription terminatorsequence, a sequence recognized by a host cell to terminatetranscription. The terminator sequence is operably linked to the 3′terminus of the nucleotide sequence encoding the polypeptide. Anyterminator that is functional in the host cell of choice may be used inthe present invention.

Preferred terminators for filamentous fungal host cells are obtainedfrom the genes for Aspergillus oryzae TAKA amylase, Aspergillus nigerglucoamylase, Aspergillus nidulans anthranilate synthase, Aspergillusniger alpha-glucosidase, and Fusarium oxysporum trypsin-like protease.

Preferred terminators for yeast host cells are obtained from the genesfor Saccharomyces cerevisiae enolase, Saccharomyces cerevisiaecytochrome C (CYC1), and Saccharomyces cerevisiaeglyceraldehyde-3-phosphate dehydrogenase. Other useful terminators foryeast host cells are described by Romanos et al., 1992, supra.

The control sequence may also be a suitable leader sequence, anontranslated region of an mRNA that is important for translation by thehost cell. The leader sequence is operably linked to the 5′ terminus ofthe nucleotide sequence encoding the polypeptide. Any leader sequencethat is functional in the host cell of choice may be used in the presentinvention.

Preferred leaders for filamentous fungal host cells are obtained fromthe genes for Aspergillus oryzae TAKA amylase and Aspergillus nidulanstriose phosphate isomerase.

Suitable leaders for yeast host cells are obtained from the genes forSaccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha-factor, andSaccharomyces cerevisiae alcoholdehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).

The control sequence may also be a polyadenylation sequence, a sequenceoperably linked to the 3′ terminus of the nucleotide sequence and, whentranscribed, is recognized by the host cell as a signal to addpolyadenosine residues to transcribed mRNA. Any polyadenylation sequencethat is functional in the host cell of choice may be used in the presentinvention.

Preferred polyadenylation sequences for filamentous fungal host cellsare obtained from the genes for Aspergillus oryzae TAKA amylase,Aspergillus niger glucoamylase, Aspergillus nidulans anthranilatesynthase, Fusarium oxysporum trypsin-like protease, and Aspergillusniger alpha-glucosidase.

Useful polyadenylation sequences for yeast host cells are described byGuo and Sherman, 1995, Molecular Cellular Biology 15: 5983-5990.

The control sequence may also be a signal peptide coding sequence thatcodes for an amino acid sequence linked to the amino terminus of apolypeptide and directs the encoded polypeptide into the cell'ssecretory pathway. The 5′ end of the coding sequence of the nucleotidesequence may inherently contain a signal peptide coding sequencenaturally linked in translation reading frame with the segment of thecoding sequence that encodes the secreted polypeptide. Alternatively,the 5′ end of the coding sequence may contain a signal peptide codingsequence that is foreign to the coding sequence. The foreign signalpeptide coding sequence may be required where the coding sequence doesnot naturally contain a signal peptide coding sequence. Alternatively,the foreign signal peptide coding sequence may simply replace thenatural signal peptide coding sequence in order to enhance secretion ofthe polypeptide. However, any signal peptide coding sequence thatdirects the expressed polypeptide into the secretory pathway of a hostcell of choice, i.e., secreted into a culture medium, may be used in thepresent invention.

Effective signal peptide coding sequences for bacterial host cells arethe signal peptide coding sequences obtained from the genes for BacillusNCIB 11837 maltogenic amylase, Bacillus stearothermophilusalpha-amylase, Bacillus licheniformis subtilisin, Bacillus licheniformisbeta-lactamase, Bacillus stearothermophilus neutral proteases (nprT,nprS, nprM), and Bacillus subtilis prsA. Further signal peptides aredescribed by Simonen and Palva, 1993, Microbiological Reviews 57:109-137.

Effective signal peptide coding sequences for filamentous fungal hostcells are the signal peptide coding sequences obtained from the genesfor Aspergillus oryzae TAKA amylase, Aspergillus niger neutral amylase,Aspergillus niger glucoamylase, Rhizomucor miehei aspartic proteinase,Humicola insolens cellulase, Humicola insolens endoglucanase V, andHumicola lanuginosa lipase.

Useful signal peptides for yeast host cells are obtained from the genesfor Saccharomyces cerevisiae alpha-factor and Saccharomyces cerevisiaeinvertase. Other useful signal peptide coding sequences are described byRomanos et al., 1992, supra.

In a preferred aspect, the signal peptide comprises or consists of aminoacids 1 to 19 of SEQ ID NO: 2. In another preferred aspect, the signalpeptide coding sequence comprises or consists of nucleotides 1 to 57 ofSEQ ID NO: 1.

The control sequence may also be a propeptide coding sequence that codesfor an amino acid sequence positioned at the amino terminus of apolypeptide. The resultant polypeptide is known as a proenzyme orpropolypeptide (or a zymogen in some cases). A propeptide is generallyinactive and can be converted to a mature active polypeptide bycatalytic or autocatalytic cleavage of the propeptide from thepropolypeptide. The propeptide coding sequence may be obtained from thegenes for Bacillus subtilis alkaline protease (aprE), Bacillus subtilisneutral protease (nprT), Saccharomyces cerevisiae alpha-factor,Rhizomucor miehei aspartic proteinase, and Myceliophthora thermophilalaccase (WO 95/33836).

Where both signal peptide and propeptide sequences are present at theamino terminus of a polypeptide, the propeptide sequence is positionednext to the amino terminus of a polypeptide and the signal peptidesequence is positioned next to the amino terminus of the propeptidesequence.

It may also be desirable to add regulatory sequences that allow theregulation of the expression of the polypeptide relative to the growthof the host cell. Examples of regulatory systems are those that causethe expression of the gene to be turned on or off in response to achemical or physical stimulus, including the presence of a regulatorycompound. Regulatory systems in prokaryotic systems include the lac,tac, and trp operator systems. In yeast, the ADH2 system or GAL1 systemmay be used. In filamentous fungi, the TAKA alpha-amylase promoter,Aspergillus niger glucoamylase promoter, and Aspergillus oryzaeglucoamylase promoter may be used as regulatory sequences. Otherexamples of regulatory sequences are those that allow for geneamplification. In eukaryotic systems, these regulatory sequences includethe dihydrofolate reductase gene that is amplified in the presence ofmethotrexate, and the metallothionein genes that are amplified withheavy metals. In these cases, the nucleotide sequence encoding thepolypeptide would be operably linked with the regulatory sequence.

Expression Vectors

The present invention also relates to recombinant expression vectorscomprising a polynucleotide of the present invention, a promoter, andtranscriptional and translational stop signals. The various nucleicacids and control sequences described herein may be joined together toproduce a recombinant expression vector that may include one or more(several) convenient restriction sites to allow for insertion orsubstitution of the nucleotide sequence encoding the polypeptide at suchsites. Alternatively, a polynucleotide sequence of the present inventionmay be expressed by inserting the nucleotide sequence or a nucleic acidconstruct comprising the sequence into an appropriate vector forexpression. In creating the expression vector, the coding sequence islocated in the vector so that the coding sequence is operably linkedwith the appropriate control sequences for expression.

The recombinant expression vector may be any vector (e.g., a plasmid orvirus) that can be conveniently subjected to recombinant DNA proceduresand can bring about expression of the nucleotide sequence. The choice ofthe vector will typically depend on the compatibility of the vector withthe host cell into which the vector is to be introduced. The vectors maybe linear or closed circular plasmids.

The vector may be an autonomously replicating vector, i.e., a vectorthat exists as an extrachromosomal entity, the replication of which isindependent of chromosomal replication, e.g., a plasmid, anextrachromosomal element, a minichromosome, or an artificial chromosome.The vector may contain any means for assuring self-replication.Alternatively, the vector may be one that, when introduced into the hostcell, is integrated into the genome and replicated together with thechromosome(s) into which it has been integrated. Furthermore, a singlevector or plasmid or two or more vectors or plasmids that togethercontain the total DNA to be introduced into the genome of the host cell,or a transposon, may be used.

The vectors of the present invention preferably contain one or more(several) selectable markers that permit easy selection of transformed,transfected, transduced, or the like cells. A selectable marker is agene the product of which provides for biocide or viral resistance,resistance to heavy metals, prototrophy to auxotrophs, and the like.

Examples of bacterial selectable markers are the dal genes from Bacillussubtilis or Bacillus licheniformis, or markers that confer antibioticresistance such as ampicillin, kanamycin, chloramphenicol, ortetracycline resistance. Suitable markers for yeast host cells are ADE2,HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in afilamentous fungal host cell include, but are not limited to, amdS(acetamidase), argB (ornithine carbamoyltransferase), bar(phosphinothricin acetyltransferase), hph (hygromycinphosphotransferase), niaD (nitrate reductase), pyrG(orotidine-5′-phosphate decarboxylase), sC (sulfate adenyltransferase),and trpC (anthranilate synthase), as well as equivalents thereof.Preferred for use in an Aspergillus cell are the amdS and pyrG genes ofAspergillus nidulans or Aspergillus oryzae and the bar gene ofStreptomyces hygroscopicus.

The vectors of the present invention preferably contain an element(s)that permits integration of the vector into the host cell's genome orautonomous replication of the vector in the cell independent of thegenome.

For integration into the host cell genome, the vector may rely on thepolynucleotide's sequence encoding the polypeptide or any other elementof the vector for integration into the genome by homologous ornonhomologous recombination. Alternatively, the vector may containadditional nucleotide sequences for directing integration by homologousrecombination into the genome of the host cell at a precise location(s)in the chromosome(s). To increase the likelihood of integration at aprecise location, the integrational elements should preferably contain asufficient number of nucleic acids, such as 100 to 10,000 base pairs,preferably 400 to 10,000 base pairs, and most preferably 800 to 10,000base pairs, which have a high degree of identity to the correspondingtarget sequence to enhance the probability of homologous recombination.The integrational elements may be any sequence that is homologous withthe target sequence in the genome of the host cell. Furthermore, theintegrational elements may be non-encoding or encoding nucleotidesequences. On the other hand, the vector may be integrated into thegenome of the host cell by non-homologous recombination.

For autonomous replication, the vector may further comprise an origin ofreplication enabling the vector to replicate autonomously in the hostcell in question. The origin of replication may be any plasmidreplicator mediating autonomous replication that functions in a cell.The term “origin of replication” or “plasmid replicator” is definedherein as a nucleotide sequence that enables a plasmid or vector toreplicate in vivo.

Examples of bacterial origins of replication are the origins ofreplication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permittingreplication in E. coli, and pUB110, pE194, pTA1060, and pAMβ1 permittingreplication in Bacillus.

Examples of origins of replication for use in a yeast host cell are the2 micron origin of replication, ARS1, ARS4, the combination of ARS1 andCEN3, and the combination of ARS4 and CEN6.

Examples of origins of replication useful in a filamentous fungal cellare AMA1 and ANSI (Gems et al., 1991, Gene 98: 61-67; Cullen et al.,1987, Nucleic Acids Research 15: 9163-9175; WO 00/24883). Isolation ofthe AMA1 gene and construction of plasmids or vectors comprising thegene can be accomplished according to the methods disclosed in WO00/24883.

More than one copy of a polynucleotide of the present invention may beinserted into a host cell to increase production of the gene product. Anincrease in the copy number of the polynucleotide can be obtained byintegrating at least one additional copy of the sequence into the hostcell genome or by including an amplifiable selectable marker gene withthe polynucleotide where cells containing amplified copies of theselectable marker gene, and thereby additional copies of thepolynucleotide, can be selected for by cultivating the cells in thepresence of the appropriate selectable agent.

The procedures used to ligate the elements described above to constructthe recombinant expression vectors of the present invention are wellknown to one skilled in the art (see, e.g., Sambrook et al., 1989,supra).

Host Cells

The present invention also relates to recombinant host cells, comprisingan isolated polynucleotide of the present invention, which areadvantageously used in the recombinant production of the polypeptides. Avector comprising a polynucleotide of the present invention isintroduced into a host cell so that the vector is maintained as achromosomal integrant or as a self-replicating extra-chromosomal vectoras described earlier. The term “host cell” encompasses any progeny of aparent cell that is not identical to the parent cell due to mutationsthat occur during replication. The choice of a host cell will to a largeextent depend upon the gene encoding the polypeptide and its source.

The host cell may be any cell useful in the recombinant production of apolypeptide of the present invention, e.g., a prokaryote or a eukaryote.

The prokaryotic host cell may be any Gram positive bacterium or a Gramnegative bacterium. Gram positive bacteria include, but not limited to,Bacillus, Streptococcus, Streptomyces, Staphylococcus, Enterococcus,Lactobacillus, Lactococcus, Clostridium, Geobacillus, andOceanobacillus. Gram negative bacteria include, but not limited to, E.coli, Pseudomonas, Salmonella, Campylobacter, Helicobacter,Flavobacterium, Fusobacterium, Ilyobacter, Neisseria, and Ureaplasma.

The bacterial host cell may be any Bacillus cell. Bacillus cells usefulin the practice of the present invention include, but are not limitedto, Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus brevis,Bacillus circulans, Bacillus clausii, Bacillus coagulans, Bacillusfirmus, Bacillus lautus, Bacillus lentus, Bacillus licheniformis,Bacillus megaterium, Bacillus pumilus, Bacillus stearothermophilus,Bacillus subtilis, and Bacillus thuringiensis cells.

In a preferred aspect, the bacterial host cell is a Bacillusamyloliquefaciens, Bacillus lentus, Bacillus licheniformis, Bacillusstearothermophilus or Bacillus subtilis cell. In a more preferredaspect, the bacterial host cell is a Bacillus amyloliquefaciens cell. Inanother more preferred aspect, the bacterial host cell is a Bacillusclausii cell. In another more preferred aspect, the bacterial host cellis a Bacillus licheniformis cell. In another more preferred aspect, thebacterial host cell is a Bacillus subtilis cell.

The bacterial host cell may also be any Streptococcus cell.Streptococcus cells useful in the practice of the present inventioninclude, but are not limited to, Streptococcus equisimilis,Streptococcus pyogenes, Streptococcus uberis, and Streptococcus equisubsp. Zooepidemicus cells.

In a preferred aspect, the bacterial host cell is a Streptococcusequisimilis cell. In another preferred aspect, the bacterial host cellis a Streptococcus pyogenes cell. In another preferred aspect, thebacterial host cell is a Streptococcus uberis cell. In another preferredaspect, the bacterial host cell is a Streptococcus equi subsp.Zooepidemicus cell.

The bacterial host cell may also be any Streptomyces cell. Streptomycescells useful in the practice of the present invention include, but arenot limited to, Streptomyces achromogenes, Streptomyces avermitilis,Streptomyces coelicolor, Streptomyces griseus, and Streptomyces lividanscells.

In a preferred aspect, the bacterial host cell is a Streptomycesachromogenes cell. In another preferred aspect, the bacterial host cellis a Streptomyces avermitilis cell. In another preferred aspect, thebacterial host cell is a Streptomyces coelicolor cell. In anotherpreferred aspect, the bacterial host cell is a Streptomyces griseuscell. In another preferred aspect, the bacterial host cell is aStreptomyces lividans cell.

The introduction of DNA into a Bacillus cell may, for instance, beeffected by protoplast transformation (see, e.g., Chang and Cohen, 1979,Molecular General Genetics 168: 111-115), by using competent cells (see,e.g., Young and Spizizen, 1961, Journal of Bacteriology 81: 823-829, orDubnau and Davidoff-Abelson, 1971, Journal of Molecular Biology 56:209-221), by electroporation (see, e.g., Shigekawa and Dower, 1988,Biotechniques 6: 742-751), or by conjugation (see, e.g., Koehler andThorne, 1987, Journal of Bacteriology 169: 5271-5278). The introductionof DNA into an E coli cell may, for instance, be effected by protoplasttransformation (see, e.g., Hanahan, 1983, J. Mol. Biol. 166: 557-580) orelectroporation (see, e.g., Dower et al., 1988, Nucleic Acids Res. 16:6127-6145). The introduction of DNA into a Streptomyces cell may, forinstance, be effected by protoplast transformation and electroporation(see, e.g., Gong et al., 2004, Folia Microbiol. (Praha) 49: 399-405), byconjugation (see, e.g., Mazodier et al., 1989, J. Bacteriol. 171:3583-3585), or by transduction (see, e.g., Burke et al., 2001, Proc.Natl. Acad. Sci. USA 98: 6289-6294). The introduction of DNA into aPseudomonas cell may, for instance, be effected by electroporation (see,e.g., Choi et al., 2006, J. Microbiol. Methods 64: 391-397) or byconjugation (see, e.g., Pinedo and Smets, 2005, Appl. Environ.Microbiol. 71: 51-57). The introduction of DNA into a Streptococcus cellmay, for instance, be effected by natural competence (see, e.g., Perryand Kuramitsu, 1981, Infect. Immun. 32: 1295-1297), by protoplasttransformation (see, e.g., Catt and Jollick, 1991, Microbios. 68:189-2070, by electroporation (see, e.g., Buckley et al., 1999, Appl.Environ. Microbiol. 65: 3800-3804) or by conjugation (see, e.g.,Clewell, 1981, Microbiol. Rev. 45: 409-436). However, any method knownin the art for introducing DNA into a host cell can be used.

The host cell may also be a eukaryote, such as a mammalian, insect,plant, or fungal cell.

In a preferred aspect, the host cell is a fungal cell. “Fungi” as usedherein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota,and Zygomycota (as defined by Hawksworth et al., In, Ainsworth andBisby's Dictionary of The Fungi, 8th edition, 1995, CAB International,University Press, Cambridge, UK) as well as the Oomycota (as cited inHawksworth et al., 1995, supra, page 171) and all mitosporic fungi(Hawksworth et al., 1995, supra).

In a more preferred aspect, the fungal host cell is a yeast cell.“Yeast” as used herein includes ascosporogenous yeast (Endomycetales),basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti(Blastomycetes). Since the classification of yeast may change in thefuture, for the purposes of this invention, yeast shall be defined asdescribed in Biology and Activities of Yeast (Skinner, F. A., Passmore,S. M., and Davenport, R. R., eds, Soc. App. Bacteriol. Symposium SeriesNo. 9, 1980).

In an even more preferred aspect, the yeast host cell is a Candida,Hansenula, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces, orYarrowia cell.

In a most preferred aspect, the yeast host cell is a Saccharomycescarlsbergensis, Saccharomyces cerevisiae, Saccharomyces diastaticus,Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomycesnorbensis, or Saccharomyces oviformis cell. In another most preferredaspect, the yeast host cell is a Kluyveromyces lactis cell. In anothermost preferred aspect, the yeast host cell is a Yarrowia lipolyticacell.

In another more preferred aspect, the fungal host cell is a filamentousfungal cell. “Filamentous fungi” include all filamentous forms of thesubdivision Eumycota and Oomycota (as defined by Hawksworth et al.,1995, supra). The filamentous fungi are generally characterized by amycelial wall composed of chitin, cellulose, glucan, chitosan, mannan,and other complex polysaccharides. Vegetative growth is by hyphalelongation and carbon catabolism is obligately aerobic. In contrast,vegetative growth by yeasts such as Saccharomyces cerevisiae is bybudding of a unicellular thallus and carbon catabolism may befermentative.

In an even more preferred aspect, the filamentous fungal host cell is anAcremonium, Aspergillus, Aureobasidium, Bjerkandera, Ceriporiopsis,Chrysosporium, Coprinus, Coriolus, Cryptococcus, Filibasidium, Fusarium,Humicola, Magnaporthe, Mucor, Myceliophthora, Neocallimastix,Neurospora, Paecilomyces, Penicillium, Phanerochaete, Phlebia,Piromyces, Pleurotus, Schizophyllum, Talaromyces, Thermoascus,Thielavia, Tolypocladium, Trametes, or Trichoderma cell.

In a most preferred aspect, the filamentous fungal host cell is anAspergillus awamori, Aspergillus fumigatus, Aspergillus foetidus,Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger orAspergillus oryzae cell. In another most preferred aspect, thefilamentous fungal host cell is a Fusarium bactridioides, Fusariumcerealis, Fusarium crookwellense, Fusarium culmorum, Fusariumgraminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi,Fusarium oxysporum, Fusarium reticulatum, Fusarium roseum, Fusariumsambucinum, Fusarium sarcochroum, Fusarium sporotrichioides, Fusariumsulphureum, Fusarium torulosum, Fusarium trichothecioides, or Fusariumvenenatum cell. In another most preferred aspect, the filamentous fungalhost cell is a Bjerkandera adusta, Ceriporiopsis aneirina, Ceriporiopsisaneirina, Ceriporiopsis caregiea, Ceriporiopsis gilvescens,Ceriporiopsis pannocinta, Ceriporiopsis rivulosa, Ceriporiopsis subrufa,Ceriporiopsis subvermispora, Chrysosporium keratinophilum, Chrysosporiumlucknowense, Chrysosporium tropicum, Chrysosporium merdarium,Chrysosporium inops, Chrysosporium pannicola, Chrysosporiumqueenslandicum, Chrysosporium zonatum, Coprinus cinereus, Coriolushirsutus, Humicola insolens, Humicola lanuginosa, Mucor miehei,Myceliophthora thermophila, Neurospora crassa, Penicillium purpurogenum,Phanerochaete chrysosporium, Phlebia radiata, Pleurotus eryngii,Thielavia terrestris, Trametes villosa, Trametes versicolor, Trichodermaharzianum, Trichoderma koningii, Trichoderma longibrachiatum,Trichoderma reesei, or Trichoderma viride cell.

Fungal cells may be transformed by a process involving protoplastformation, transformation of the protoplasts, and regeneration of thecell wall in a manner known per se. Suitable procedures fortransformation of Aspergillus and Trichoderma host cells are describedin EP 238 023 and Yelton et al., 1984, Proceedings of the NationalAcademy of Sciences USA 81: 1470-1474. Suitable methods for transformingFusarium species are described by Malardier et al., 1989, Gene 78:147-156, and WO 96/00787. Yeast may be transformed using the proceduresdescribed by Becker and Guarente, In Abelson, J. N. and Simon, M. I.,editors, Guide to Yeast Genetics and Molecular Biology, Methods inEnzymology, Volume 194, pp 182-187, Academic Press, Inc., New York; Itoet al., 1983, Journal of Bacteriology 153: 163; and Hinnen et al., 1978,Proceedings of the National Academy of Sciences USA 75: 1920.

Methods of Production

The present invention also relates to methods of producing a polypeptideof the present invention, comprising: (a) cultivating a cell, which inits wild-type form produces the polypeptide, under conditions conducivefor production of the polypeptide; and (b) recovering the polypeptide.In a preferred aspect, the cell is of the genus Humicola. In a morepreferred aspect, the cell is Humicola insolens. In a most preferredaspect, the cell is Humicola insolens DSM 1800.

The present invention also relates to methods of producing a polypeptideof the present invention, comprising: (a) cultivating a recombinant hostcell, as described herein, under conditions conducive for production ofthe polypeptide; and (b) recovering the polypeptide.

The present invention also relates to methods of producing a polypeptideof the present invention, comprising: (a) cultivating a recombinant hostcell under conditions conducive for production of the polypeptide,wherein the host cell comprises a mutant nucleotide sequence having atleast one mutation in the mature polypeptide coding sequence of SEQ IDNO: 1, wherein the mutant nucleotide sequence encodes a polypeptide thatcomprises or consists of the mature polypeptide of SEQ ID NO: 2; and (b)recovering the polypeptide.

In the production methods of the present invention, the cells arecultivated in a nutrient medium suitable for production of thepolypeptide using methods well known in the art. For example, the cellmay be cultivated by shake flask cultivation, and small-scale orlarge-scale fermentation (including continuous, batch, fed-batch, orsolid state fermentations) in laboratory or industrial fermentorsperformed in a suitable medium and under conditions allowing thepolypeptide to be expressed and/or isolated. The cultivation takes placein a suitable nutrient medium comprising carbon and nitrogen sources andinorganic salts, using procedures known in the art. Suitable media areavailable from commercial suppliers or may be prepared according topublished compositions (e.g., in catalogues of the American Type CultureCollection). If the polypeptide is secreted into the nutrient medium,the polypeptide can be recovered directly from the medium. If thepolypeptide is not secreted into the medium, it can be recovered fromcell lysates.

The polypeptides may be detected using methods known in the art that arespecific for the polypeptides. These detection methods may include useof specific antibodies, formation of an enzyme product, or disappearanceof an enzyme substrate. For example, an enzyme assay may be used todetermine the activity of the polypeptide as described herein.

The resulting polypeptide may be recovered using methods known in theart. For example, the polypeptide may be recovered from the nutrientmedium by conventional procedures including, but not limited to,centrifugation, filtration, extraction, spray-drying, evaporation, orprecipitation.

The polypeptides of the present invention may be purified by a varietyof procedures known in the art including, but not limited to,chromatography (e.g., ion exchange, affinity, hydrophobic,chromatofocusing, and size exclusion), electrophoretic procedures (e.g.,preparative isoelectric focusing), differential solubility (e.g.,ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g.,Protein Purification, J.-C. Janson and Lars Ryden, editors, VCHPublishers, New York, 1989) to obtain substantially pure polypeptides.

Plants

The present invention also relates to plants, e.g., a transgenic plant,plant part, or plant cell, comprising an isolated polynucleotideencoding a polypeptide having acetylxylan esterase activity of thepresent invention so as to express and produce the polypeptide inrecoverable quantities. The polypeptide may be recovered from the plantor plant part. Alternatively, the plant or plant part containing therecombinant polypeptide may be used as such for improving the quality ofa food or feed, e.g., improving nutritional value, palatability, andrheological properties, or to destroy an antinutritive factor.

The transgenic plant can be dicotyledonous (a dicot) or monocotyledonous(a monocot). Examples of monocot plants are grasses, such as meadowgrass (blue grass, Poa), forage grass such as Festuca, Lolium, temperategrass, such as Agrostis, and cereals, e.g., wheat, oats, rye, barley,rice, sorghum, and maize (corn).

Examples of dicot plants are tobacco, legumes, such as lupins, potato,sugar beet, pea, bean and soybean, and cruciferous plants (familyBrassicaceae), such as cauliflower, rape seed, and the closely relatedmodel organism Arabidopsis thaliana.

Examples of plant parts are stem, callus, leaves, root, fruits, seeds,and tubers as well as the individual tissues comprising these parts,e.g., epidermis, mesophyll, parenchyme, vascular tissues, meristems.Specific plant cell compartments, such as chloroplasts, apoplasts,mitochondria, vacuoles, peroxisomes and cytoplasm are also considered tobe a plant part. Furthermore, any plant cell, whatever the tissueorigin, is considered to be a plant part. Likewise, plant parts such asspecific tissues and cells isolated to facilitate the utilisation of theinvention are also considered plant parts, e.g., embryos, endosperms,aleurone and seeds coats.

Also included within the scope of the present invention are the progenyof such plants, plant parts, and plant cells.

The transgenic plant or plant cell expressing a polypeptide of thepresent invention may be constructed in accordance with methods known inthe art. In short, the plant or plant cell is constructed byincorporating one or more (several) expression constructs encoding apolypeptide of the present invention into the plant host genome orchloroplast genome and propagating the resulting modified plant or plantcell into a transgenic plant or plant cell.

The expression construct is conveniently a nucleic acid construct thatcomprises a polynucleotide encoding a polypeptide of the presentinvention operably linked with appropriate regulatory sequences requiredfor expression of the nucleotide sequence in the plant or plant part ofchoice. Furthermore, the expression construct may comprise a selectablemarker useful for identifying host cells into which the expressionconstruct has been integrated and DNA sequences necessary forintroduction of the construct into the plant in question (the latterdepends on the DNA introduction method to be used).

The choice of regulatory sequences, such as promoter and terminatorsequences and optionally signal or transit sequences is determined, forexample, on the basis of when, where, and how the polypeptide is desiredto be expressed. For instance, the expression of the gene encoding apolypeptide of the present invention may be constitutive or inducible,or may be developmental, stage or tissue specific, and the gene productmay be targeted to a specific tissue or plant part such as seeds orleaves. Regulatory sequences are, for example, described by Tague etal., 1988, Plant Physiology 86: 506.

For constitutive expression, the 35S-CaMV, the maize ubiquitin 1, andthe rice actin 1 promoter may be used (Franck et al., 1980, Cell 21:285-294, Christensen et al., 1992, Plant Mo. Biol. 18: 675-689; Zhang etal., 1991, Plant Cell 3: 1155-1165). organ-specific promoters may be,for example, a promoter from storage sink tissues such as seeds, potatotubers, and fruits (Edwards & Coruzzi, 1990, Ann. Rev. Genet. 24:275-303), or from metabolic sink tissues such as meristems (Ito et al.,1994, Plant Mol. Biol. 24: 863-878), a seed specific promoter such asthe glutelin, prolamin, globulin, or albumin promoter from rice (Wu etal., 1998, Plant and Cell Physiology 39: 885-889), a Vicia faba promoterfrom the legumin B4 and the unknown seed protein gene from Vicia faba(Conrad et al., 1998, Journal of Plant Physiology 152: 708-711), apromoter from a seed oil body protein (Chen et al., 1998, Plant and CellPhysiology 39: 935-941), the storage protein napA promoter from Brassicanapus, or any other seed specific promoter known in the art, e.g., asdescribed in WO 91/14772. Furthermore, the promoter may be a leafspecific promoter such as the rbcs promoter from rice or tomato (Kyozukaet al., 1993, Plant Physiology 102: 991-1000, the chlorella virusadenine methyltransferase gene promoter (Mitra and Higgins, 1994, PlantMolecular Biology 26: 85-93), or the aldP gene promoter from rice(Kagaya et al., 1995, Molecular and General Genetics 248: 668-674), or awound inducible promoter such as the potato pin2 promoter (Xu et al.,1993, Plant Molecular Biology 22: 573-588). Likewise, the promoter mayinducible by abiotic treatments such as temperature, drought, oralterations in salinity or induced by exogenously applied substancesthat activate the promoter, e.g., ethanol, oestrogens, plant hormonessuch as ethylene, abscisic acid, and gibberellic acid, and heavy metals.

A promoter enhancer element may also be used to achieve higherexpression of a polypeptide of the present invention in the plant. Forinstance, the promoter enhancer element may be an intron that is placedbetween the promoter and the nucleotide sequence encoding a polypeptideof the present invention. For instance, Xu et al., 1993, supra, disclosethe use of the first intron of the rice actin 1 gene to enhanceexpression.

The selectable marker gene and any other parts of the expressionconstruct may be chosen from those available in the art.

The nucleic acid construct is incorporated into the plant genomeaccording to conventional techniques known in the art, includingAgrobacterium-mediated transformation, virus-mediated transformation,microinjection, particle bombardment, biolistic transformation, andelectroporation (Gasser et al., 1990, Science 244: 1293; Potrykus, 1990,Bio/Technology 8: 535; Shimamoto et al., 1989, Nature 338: 274).

Presently, Agrobacterium tumefaciens-mediated gene transfer is themethod of choice for generating transgenic dicots (for a review, seeHooykas and Schilperoort, 1992, Plant Molecular Biology 19: 15-38) andcan also be used for transforming monocots, although othertransformation methods are often used for these plants. Presently, themethod of choice for generating transgenic monocots is particlebombardment (microscopic gold or tungsten particles coated with thetransforming DNA) of embryonic calli or developing embryos (Christou,1992, Plant Journal 2: 275-281; Shimamoto, 1994, Current OpinionBiotechnology 5: 158-162; Vasil et al., 1992, Bio/Technology 10:667-674). An alternative method for transformation of monocots is basedon protoplast transformation as described by Omirulleh et al., 1993,Plant Molecular Biology 21: 415-428.

Following transformation, the transformants having incorporated theexpression construct are selected and regenerated into whole plantsaccording to methods well-known in the art. Often the transformationprocedure is designed for the selective elimination of selection geneseither during regeneration or in the following generations by using, forexample, co-transformation with two separate T-DNA constructs or sitespecific excision of the selection gene by a specific recombinase.

The present invention also relates to methods of producing a polypeptideof the present invention comprising: (a) cultivating a transgenic plantor a plant cell comprising a polynucleotide encoding the polypeptidehaving acetylxylan esterase activity of the present invention underconditions conducive for production of the polypeptide; and (b)recovering the polypeptide.

Removal or Reduction of Acetylxylan Esterase Activity

The present invention also relates to methods of producing a mutant of aparent cell, which comprises disrupting or deleting a polynucleotidesequence, or a portion thereof, encoding a polypeptide of the presentinvention, which results in the mutant cell producing less of thepolypeptide than the parent cell when cultivated under the sameconditions.

The mutant cell may be constructed by reducing or eliminating expressionof a nucleotide sequence encoding a polypeptide of the present inventionusing methods well known in the art, for example, insertions,disruptions, replacements, or deletions. In a preferred aspect, thenucleotide sequence is inactivated. The nucleotide sequence to bemodified or inactivated may be, for example, the coding region or a partthereof essential for activity, or a regulatory element required for theexpression of the coding region. An example of such a regulatory orcontrol sequence may be a promoter sequence or a functional partthereof, i.e., a part that is sufficient for affecting expression of thenucleotide sequence. Other control sequences for possible modificationinclude, but are not limited to, a leader, polyadenylation sequence,propeptide sequence, signal peptide sequence, transcription terminator,and transcriptional activator.

Modification or inactivation of the nucleotide sequence may be performedby subjecting the parent cell to mutagenesis and selecting for mutantcells in which expression of the nucleotide sequence has been reduced oreliminated. The mutagenesis, which may be specific or random, may beperformed, for example, by use of a suitable physical or chemicalmutagenizing agent, by use of a suitable oligonucleotide, or bysubjecting the DNA sequence to PCR generated mutagenesis. Furthermore,the mutagenesis may be performed by use of any combination of thesemutagenizing agents.

Examples of a physical or chemical mutagenizing agent suitable for thepresent purpose include ultraviolet (UV) irradiation, hydroxylamine,N-methyl-N′-nitro-N-nitrosoguanidine (MNNG), O-methyl hydroxylamine,nitrous acid, ethyl methane sulphonate (EMS), sodium bisulphite, formicacid, and nucleotide analogues.

When such agents are used, the mutagenesis is typically performed byincubating the parent cell to be mutagenized in the presence of themutagenizing agent of choice under suitable conditions, and screeningand/or selecting for mutant cells exhibiting reduced or no expression ofthe gene.

Modification or inactivation of the nucleotide sequence may beaccomplished by introduction, substitution, or removal of one or more(several) nucleotides in the gene or a regulatory element required forthe transcription or translation thereof. For example, nucleotides maybe inserted or removed so as to result in the introduction of a stopcodon, the removal of the start codon, or a change in the open readingframe. Such modification or inactivation may be accomplished bysite-directed mutagenesis or PCR generated mutagenesis in accordancewith methods known in the art. Although, in principle, the modificationmay be performed in vivo, i.e., directly on the cell expressing thenucleotide sequence to be modified, it is preferred that themodification be performed in vitro as exemplified below.

An example of a convenient way to eliminate or reduce expression of anucleotide sequence by a cell is based on techniques of genereplacement, gene deletion, or gene disruption. For example, in the genedisruption method, a nucleic acid sequence corresponding to theendogenous nucleotide sequence is mutagenized in vitro to produce adefective nucleic acid sequence that is then transformed into the parentcell to produce a defective gene. By homologous recombination, thedefective nucleic acid sequence replaces the endogenous nucleotidesequence. It may be desirable that the defective nucleotide sequencealso encodes a marker that may be used for selection of transformants inwhich the nucleotide sequence has been modified or destroyed. In aparticularly preferred aspect, the nucleotide sequence is disrupted witha selectable marker such as those described herein.

Alternatively, modification or inactivation of the nucleotide sequencemay be performed by established anti-sense or RNAi techniques using asequence complementary to the nucleotide sequence. More specifically,expression of the nucleotide sequence by a cell may be reduced oreliminated by introducing a sequence complementary to the nucleotidesequence of the gene that may be transcribed in the cell and is capableof hybridizing to the mRNA produced in the cell. Under conditionsallowing the complementary anti-sense nucleotide sequence to hybridizeto the mRNA, the amount of protein translated is thus reduced oreliminated.

The present invention further relates to a mutant cell of a parent cellthat comprises a disruption or deletion of a nucleotide sequenceencoding the polypeptide or a control sequence thereof, which results inthe mutant cell producing less of the polypeptide or no polypeptidecompared to the parent cell.

The polypeptide-deficient mutant cells so created are particularlyuseful as host cells for the expression of native and/or heterologouspolypeptides. Therefore, the present invention further relates tomethods of producing a native or heterologous polypeptide comprising:(a) cultivating the mutant cell under conditions conducive forproduction of the polypeptide; and (b) recovering the polypeptide. Theterm “heterologous polypeptides” is defined herein as polypeptides thatare not native to the host cell, a native protein in which modificationshave been made to alter the native sequence, or a native protein whoseexpression is quantitatively altered as a result of a manipulation ofthe host cell by recombinant DNA techniques.

In a further aspect, the present invention relates to a method ofproducing a protein product essentially free of acetylxylan esteraseactivity by fermentation of a cell that produces both a polypeptide ofthe present invention as well as the protein product of interest byadding an effective amount of an agent capable of inhibiting acetylxylanesterase activity to the fermentation broth before, during, or after thefermentation has been completed, recovering the product of interest fromthe fermentation broth, and optionally subjecting the recovered productto further purification.

In a further aspect, the present invention relates to a method ofproducing a protein product essentially free of acetylxylan esteraseactivity by cultivating the cell under conditions permitting theexpression of the product, subjecting the resultant culture broth to acombined pH and temperature treatment so as to reduce the acetylxylanesterase activity substantially, and recovering the product from theculture broth. Alternatively, the combined pH and temperature treatmentmay be performed on an enzyme preparation recovered from the culturebroth. The combined pH and temperature treatment may optionally be usedin combination with a treatment with an acetylxylan esterase inhibitor.

In accordance with this aspect of the invention, it is possible toremove at least 60%, preferably at least 75%, more preferably at least85%, still more preferably at least 95%, and most preferably at least99% of the acetylxylan esterase activity. Complete removal ofacetylxylan esterase activity may be obtained by use of this method.

The combined pH and temperature treatment is preferably carried out at apH in the range of 2-4 or 9-11 and a temperature in the range of atleast 60-70° C. for a sufficient period of time to attain the desiredeffect, where typically, 30 to 60 minutes is sufficient.

The methods used for cultivation and purification of the product ofinterest may be performed by methods known in the art.

The methods of the present invention for producing an essentiallyacetylxylan esterase-free product is of particular interest in theproduction of eukaryotic polypeptides, in particular fungal proteinssuch as enzymes. The enzyme may be selected from, e.g., an amylolyticenzyme, lipolytic enzyme, proteolytic enzyme, cellulolytic enzyme,oxidoreductase, or plant cell-wall degrading enzyme. Examples of suchenzymes include an aminopeptidase, amylase, amyloglucosidase,carbohydrase, carboxypeptidase, catalase, cellobiohydrolase, cellulase,chitinase, cutinase, cyclodextrin glycosyltransferase,deoxyribonuclease, endoglucanase, esterase, galactosidase,beta-galactosidase, glucoamylase, glucose oxidase, glucosidase,haloperoxidase, hemicellulase, invertase, isomerase, laccase, ligase,lipase, lyase, mannosidase, oxidase, pectinolytic enzyme, peroxidase,phytase, phenoloxidase, polyphenoloxidase, proteolytic enzyme,ribonuclease, transferase, transglutaminase, or xylanase. Theacetylxylan esterase-deficient cells may also be used to expressheterologous proteins of pharmaceutical interest such as hormones,growth factors, receptors, and the like.

It will be understood that the term “eukaryotic polypeptides” includesnot only native polypeptides, but also those polypeptides, e.g.,enzymes, which have been modified by amino acid substitutions, deletionsor additions, or other such modifications to enhance activity,thermostability, pH tolerance and the like.

In a further aspect, the present invention relates to a protein productessentially free from acetylxylan esterase activity that is produced bya method of the present invention.

Methods of Inhibiting Expression of a Polypeptide having AcetylxylanEsterase Activity

The present invention also relates to methods of inhibiting theexpression of a polypeptide of the present invention in a cell,comprising administering to the cell or expressing in the cell adouble-stranded RNA (dsRNA) molecule, wherein the dsRNA comprises asubsequence of a polynucleotide of the present invention. In a preferredaspect, the dsRNA is about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 ormore duplex nucleotides in length.

The dsRNA is preferably a small interfering RNA (siRNA) or a micro RNA(miRNA). In a preferred aspect, the dsRNA is small interfering RNA(siRNAs) for inhibiting transcription. In another preferred aspect, thedsRNA is micro RNA (miRNAs) for inhibiting translation.

The present invention also relates to such double-stranded RNA (dsRNA)molecules, comprising a portion of the mature polypeptide codingsequence of SEQ ID NO: 1 for inhibiting expression of a polypeptide in acell. While the present invention is not limited by any particularmechanism of action, the dsRNA can enter a cell and cause thedegradation of a single-stranded RNA (ssRNA) of similar or identicalsequences, including endogenous mRNAs. When a cell is exposed to dsRNA,mRNA from the homologous gene is selectively degraded by a processcalled RNA interference (RNAi).

The dsRNAs of the present invention can be used in gene-silencingtherapeutics. In one aspect, the invention provides methods toselectively degrade RNA using the dsRNAis of the present invention. Theprocess may be practiced in vitro, ex vivo or in vivo. In one aspect,the dsRNA molecules can be used to generate a loss-of-function mutationin a cell, an organ or an animal. Methods for making and using dsRNAmolecules to selectively degrade RNA are well known in the art, see, forexample, U.S. Pat. No. 6,506,559; U.S. Pat. No. 6,511,824; U.S. Pat. No.6,515,109; and U.S. Pat. No. 6,489,127.

Compositions

The present invention also relates to compositions comprising apolypeptide of the present invention. Preferably, the compositions areenriched in such a polypeptide. The term “enriched” indicates that theacetylxylan esterase activity of the composition has been increased,e.g., with an enrichment factor of at least 1.1.

The composition may comprise a polypeptide of the present invention asthe major enzymatic component, e.g., a mono-component composition.Alternatively, the composition may comprise multiple enzymaticactivities, such as an aminopeptidase, amylase, carbohydrase,carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextringlycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase,beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase,haloperoxidase, invertase, laccase, lipase, mannosidase, oxidase,pectinolytic enzyme, peptidoglutaminase, peroxidase, phytase,polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase,or xylanase. The additional enzyme(s) may be produced, for example, by amicroorganism belonging to the genus Aspergillus, preferably Aspergillusaculeatus, Aspergillus awamori, Aspergillus fumigatus, Aspergillusfoetidus, Aspergillus japonicus, Aspergillus nidulans, Aspergillusniger, or Aspergillus oryzae; Fusarium, preferably Fusariumbactridioides, Fusarium cerealis, Fusarium crookwellense, Fusariumculmorum, Fusarium graminearum, Fusarium graminum, Fusariumheterosporum, Fusarium negundi, Fusarium oxysporum, Fusariumreticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum,Fusarium sulphureum, Fusarium toruloseum, Fusarium trichothecioides, orFusarium venenatum; Humicola, preferably Humicola insolens or Humicolalanuginosa; or Trichoderma, preferably Trichoderma harzianum,Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma reesei,or Trichoderma viride.

The polypeptide compositions may be prepared in accordance with methodsknown in the art and may be in the form of a liquid or a drycomposition. For instance, the polypeptide composition may be in theform of a granulate or a microgranulate. The polypeptide to be includedin the composition may be stabilized in accordance with methods known inthe art.

Examples are given below of preferred uses of the polypeptidecompositions of the invention. The dosage of the polypeptide compositionof the invention and other conditions under which the composition isused may be determined on the basis of methods known in the art.

Uses

The present invention is also directed to methods for using thepolypeptides having acetylxylan esterase activity.

The polypeptides of the present invention can be used for degradation ormodification of plant cell walls or any xylan-containing materialoriginating from plant cells walls. Examples of various uses aredescribed below (see, WO 2002/18561, for other uses). The dosage of thepolypeptides of the present invention and other conditions under whichthe preparation is used may be determined on the basis of methods knownin the art.

The enzymatic degradation of xylan is facilitated by full or partialremoval of the side branches. The polypeptides of the present inventionare preferably used in conjunction with other xylan degrading enzymessuch as xylanases, acetylxylan esterases, arabinofuranosidases,xylosidases, feruloyl esterases, glucuronidases, and a combinationthereof, in processes wherein xylan is to be degraded. For example,acetyl groups can be removed by acetylxylan esterases; arabinose groupsby alpha-arabinosidases; feruloyl groups by feruloyl esterases, andglucuronic acid groups by alpha-glucuronidases. The oligomers releasedby the xylanases, or by a combination of xylanases and sidebranch-hydrolyzing enzymes, can be further degraded to free xylose bybeta-xylosidases. A polypeptide of the present invention is preferably acomponent of a composition comprising one or more (several) xylandegrading enzymes, in particular xylanase. In the various uses describedbelow, a polypeptide of the present invention is preferably used incombination with one or more (several) xylan degrading enzymes.

Consequently, the present invention also relates to methods fordegrading a xylan-containing material, comprising treating thexylan-containing material with such a polypeptide having acetylxylanesterase activity. In a preferred aspect, the xylan-containing materialis further treated with a xylan degrading enzyme. The xylan degradingenzyme can be selected from the group consisting of a xylanase, anacetyxylan esterase, a feruloyl esterase, an arabinofuranosidase, axylosidase, a glucuronidase, and a combination thereof.

The plant material may be degraded in order to improve different kindsof processing, facilitate purification or extraction of components otherthan the xylans, like purification of beta-glucan or beta-glucanoligomers from cereals, improve the feed value, decrease the waterbinding capacity, improve the degradability in waste water plants,improve the conversion of, for example, grass and corn to ensilage, etc.The polypeptides of the present invention may be used in the enzymatichydrolysis of various plant cell wall-derived materials or wastematerials, e.g., from paper production, or agricultural residues such aswheat-straw, corn cobs, corn fiber, whole corn plants, nut shells,grass, vegetable hulls, bean hulls, spent grains, sugar beet pulp, andthe like. The polypeptides may also be used for modifying the viscosityof plant cell wall derived material. For instance, the polypeptides maybe used to reduce the viscosity of xylan-containing material, to promoteprocessing of viscous xylan-containing material, such as in wheatseparation.

The polypeptides of the present invention may also be used with limitedactivity of other xylanolytic enzymes to degrade xylans for productionof oligosaccharides. The oligosaccharides may be used as bulking agents,like arabinoxylan oligosaccharides released from cereal cell wallmaterial, or of more or less purified arabinoxylans from cereals.

The polypeptides of the present invention may also be used incombination with other xylanolytic enzymes to degrade xylans to xyloseand other monosaccharides (U.S. Pat. No. 5,658,765). The released xylosemay be converted to other compounds.

The polypeptides of the present invention may also be used inlignocellulosic biomass degradation or conversion to fermentable sugarsfor the production of, for example, fuel, potable ethanol, and/orfermentation products (e.g., acids, alcohols, ketones, gases, and thelike). The polypeptides are preferably used in combination with otherxylan degrading enzymes and a cellulase composition (endoglucanase(s),cellobiohydrolase(s), and beta-glucosidase(s)).

The polypeptides of the present invention may be used together withother enzymes like glucanases to improve the extraction of oil fromoil-rich plant material, like corn-oil from corn-embryos.

The polypeptides of the present invention may also be used in baking toimprove the development, elasticity, and/or stability of dough and/orthe volume, crumb structure, and/or anti-staling properties of the bakedproduct. The polypeptides may be used for the preparation of dough orbaked products prepared from any type of flour or meal (e.g., based onwheat, rye, barley, oat, or maize). The baked products produced with apolypeptide of the present invention include bread, rolls, baguettes andthe like. For baking purposes a polypeptide of the present invention maybe used as the only or major enzymatic activity, or may be used incombination with other enzymes such as a xylanase, a lipase, an amylase,an oxidase (e.g., glucose oxidase, peroxidase), a laccase and/or aprotease.

The polypeptides of the present invention may also be used formodification of animal feed and may exert their effect either in vitro(by modifying components of the feed) or in vivo. The polypeptides maybe added to animal feed compositions containing high amounts ofarabinoxylans and glucuronoxylans, e.g., feed containing cereals such asbarley, wheat, rye, oats, or maize. When added to feed the polypeptidewill improve the in vivo break-down of plant cell wall material partlydue to a reduction of intestinal viscosity (Bedford et al., 1993,Proceedings of the 1st Symposium on Enzymes in Animal Nutrition, pp.73-77), whereby improved utilization of the plant nutrients by theanimal is achieved. Thereby, the growth rate and/or feed conversionratio (i.e., the weight of ingested feed relative to weight gain) of theanimal is improved.

The polypeptides of the present invention may also be used in the paperand pulp industry, inter alia in bleaching processes to enhance thebrightness of bleached pulps whereby the amount of chlorine used in thebleaching stages is reduced, and to increase the freeness of pulps inthe recycled paper process (Eriksson, 1990, Wood Science and Technology24: 79-101; Paice et al., 1988, Biotechnol. and Bioeng. 32: 235-239, andPommier et al., 1989, Tappi Journal 187-191). Furthermore, thepolypeptides may be used for treatment of lignocellulosic pulp so as toimprove the bleachability thereof. The treatment of lignocellulosic pulpmay be performed, for example, as described in U.S. Pat. No. 5,658,765,WO 93/08275, WO 91/02839, and WO 92/03608.

The polypeptides of the present invention may also be used in beerbrewing, in particular to improve the filterability of wort containing,for example, barley and/or sorghum malt (WO 2002/24926). Thepolypeptides may be used in the same manner as pentosanasesconventionally used for brewing, e.g., as described by Viëtor et al.,1993, J. Inst. Brew. 99: 243-248; and EP 227159. Furthermore, thepolypeptides may be used for treatment of brewers spent grain, i.e.,residuals from beer wort production containing barley or malted barleyor other cereals, so as to improve the utilization of the residuals for,e.g., animal feed.

The polypeptides of the present invention may be used for separation ofcomponents of plant cell materials, in particular of cereal componentssuch as wheat components. Of particular interest is the separation ofwheat into gluten and starch, i.e., components of considerablecommercial interest. The separation process may be performed by use ofmethods known in the art, conveniently a so-called batter process (orwet milling process) performed as a hydroclone or a decanter process. Inthe batter process, the starting material is a dilute pumpabledispersion of the plant material such as wheat to be subjected toseparation. In a wheat separation process the dispersion is madenormally from wheat flour and water.

The polypeptides of the invention may also be used in the preparation offruit or vegetable juice in order to increase yield.

The polypeptides of the present invention may also be used as acomponent of an enzymatic scouring system for textiles.

The polypeptides of the present invention may also be used in laundrydetergent applications in combination with other enzyme functionalities.

Signal Peptide

The present invention also relates to nucleic acid constructs comprisinga gene encoding a protein, wherein the gene is operably linked to anucleotide sequence encoding a signal peptide comprising or consistingof amino acids 1 to 19 of SEQ ID NO: 2, wherein the gene is foreign tothe nucleotide sequence.

In a preferred aspect, the nucleotide sequence comprises or consists ofnucleotides 1 to 57 of SEQ ID NO: 1.

The present invention also relates to recombinant expression vectors andrecombinant host cells comprising such nucleic acid constructs.

The present invention also relates to methods of producing a proteincomprising (a) cultivating such a recombinant host cell under conditionssuitable for production of the protein; and (b) recovering the protein.

The protein may be native or heterologous to a host cell. The term“protein” is not meant herein to refer to a specific length of theencoded product and, therefore, encompasses peptides, oligopeptides, andproteins. The term “protein” also encompasses two or more polypeptidescombined to form the encoded product. The proteins also include hybridpolypeptides that comprise a combination of partial or completepolypeptide sequences obtained from at least two different proteinswherein one or more (several) may be heterologous or native to the hostcell. Proteins further include naturally occurring allelic andengineered variations of the above mentioned proteins and hybridproteins.

Preferably, the protein is a hormone or variant thereof, enzyme,receptor or portion thereof, antibody or portion thereof, or reporter.In a more preferred aspect, the protein is an oxidoreductase,transferase, hydrolase, lyase, isomerase, or ligase. In an even morepreferred aspect, the protein is an aminopeptidase, amylase,carbohydrase, carboxypeptidase, catalase, cellulase, chitinase,cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase,alpha-galactosidase, beta-galactosidase, glucoamylase,alpha-glucosidase, beta-glucosidase, invertase, laccase, another lipase,mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase,phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease,transglutaminase or xylanase.

The gene may be obtained from any prokaryotic, eukaryotic, or othersource.

The present invention is further described by the following examplesthat should not be construed as limiting the scope of the invention.

EXAMPLES Materials

Chemicals used as buffers and substrates were commercial products of atleast reagent grade.

Strains

Humicola insolens DSM 1800 was used as the source of a Family CE1 geneencoding a polypeptide having acetylxylan esterase activity. Aspergillusniger MBin120 strain (WO 2004/090155) was used for expression of theHumicola insolens gene encoding the polypeptide having acetylxylanesterase activity.

Media

PDA plates were composed per liter of 39 g of potato dextrose agar.

YP medium was composed per liter of 10 g of yeast extract and 20 g ofBacto peptone.

COVE A urea-acetamide+plates were composed per liter of 20 ml of COVE Asalts solution, 220 g of sorbitol, 10 g of glucose, 10 ml of 1 Macetamide, and 30 g of Bacto agar; pH 5.2.

COVE A salts solution was composed per liter of 26 g of KCl, 26 g ofMgSO₄, 76 g of KH₂PO₄, and 50 ml of COVE A trace elements solution.

COVE trace elements solution was composed per liter of 0.04 g ofNa₂B₄O₇.10H₂O, 0.4 g of CuSO₄.5H₂O, 1.2 g of FeSO₄.7H₂O, 0.7 g ofMnSO₄.H₂O, 0.8 g of Na₂MoO₂.2H₂O, and 10 g of ZnSO₄.7H₂O.

M410 medium was composed per liter of 50 g of maltose, 50 g of glucose,2 g of MgSO₄.7H₂O, 2 g of KH₂PO_(4,) 4 g of citric acid anhydrouspowder, 8 g of yeast extract, 2 g of urea, 0.5 g of AMG trace metalssolution, and 0.5 g of CaCl₂; pH 6.0.

AMG trace metals solution was composed per liter of 14.3 g ofZnSO₄.7H₂O, 2.5 g of CuSO₄.5H₂O, 0.5 g of NiCl₂.6H₂O, 13.8 g ofFeSO₄.7H₂O, 8.5 g of MnSO₄.7H₂O, and 3 g of citric acid.

LB medium was composed per liter of 10 g of tryptone, 5 g of yeastextract, and 5 g of NaCl.

Example 1 Identification of Humicola insolens acetylxylan esterase

Protein Fractionation of ULTRAFLO® L. A 2 ml aliquot of ULTRAFLO® L(Novozymes NS, Bagsværd, Denmark) was first buffer-exchanged into 20 mMsodium acetate pH 5 with 150 mM sodium chloride, using a HIPREP™ 26/10Desalting Column (GE Healthcare, Piscataway, N.J., USA). The resultingbuffer-exchanged material (18.5 ml) was then concentrated to 3 ml usingultrafiltration with a VIVASPIN® 20 spin column with a 3,000 Daltonmolecular weight cut-off membrane (Vivascience AG, Hannover, Germany). A2 ml aliquot of the buffer-exchanged and concentrated ULTRAFLO® Lmaterial was then fractionated by size-exclusion chromatography over aHILOAD™ 26/60 SUPERDEX™ 200 prep grade size exclusion column (GEHealthcare, Piscataway, N.J., USA) by isocratic elution with the samebuffer. Fractions showing UV absorbance at 280 nm were combined into sixseparate pools from varying elution times, ranging from 20-40 ml totalvolume each. Pooled fractions were concentrated to between 1-5 ml usingultrafiltration with a VIVASPIN® 20 spin column with a 3,000 Damolecular weight cut-off membrane. Twenty pl of each concentrated pooledfraction were separated on a CRITERION™ 8-16% Tris-HCl SDS-PAGE gel(Bio-Rad Laboratories, Inc., Hercules, Calif., USA) according to themanufacturer's suggested conditions. PRECISION PLUS PROTEIN™ Standards(Bio-Rad Laboratories, Inc., Hercules, Calif., USA) were used asmolecular weight markers. The gel was stained with BIO-SAFE™ Coomassiestain (Bio-Rad Laboratories, Inc., Hercules, Calif., USA), and visiblebands were excised with a razor blade for protein identificationanalysis.

In-gel digestion of polypeptides for peptide sequencing. A MULTIPROBE®II Liquid Handling Robot (PerkinElmer Life and Analytical Sciences,Boston, Mass., USA) was used to perform the in-gel digestions. A 30 kDaprotein gel band was reduced with 50 μl of 10 mM dithiothreitol (DTT) in100 mM ammonium bicarbonate pH 8.0 for 30 minutes. Following reduction,the gel piece was alkylated with 50 μl of 55 mM iodoacetamide in 100 mMammonium bicarbonate pH 8.0 for 20 minutes. The dried gel piece wasallowed to swell in 25 μl of a trypsin digestion solution containing 6ng of sequencing grade trypsin (Promega, Madison, Wis., USA) per μl of50 mM ammonium bicarbonate pH 8 for 30 minutes at room temperature,followed by an 8 hour digestion at 40° C. Each of the reaction stepsdescribed above was followed by numerous washes and pre-washes with theappropriate solutions following the manufacturer's standard protocol.Fifty μl of acetonitrile was used to de-hydrate the gel piece betweenreactions and the gel piece was air dried between steps. Peptides wereextracted twice with 1% formic acid/2% acetonitrile in HPLC grade waterfor 30 minutes. Peptide extraction solutions were transferred to a 96well skirted PCR type plate (ABGene, Rochester, N.Y., USA) that had beencooled to 10-15° C. and covered with a 96-well plate lid (PerkinElmerLife and Analytical Sciences, Boston, Mass., USA) to preventevaporation. Plates were further stored at 4° C. until mass spectrometryanalysis could be performed.

Protein Identification. For de novo peptide sequencing by tandem massspectrometry, a Q-TOFMICRO™ (Waters Micromass MS Technologies, Milford,Mass., USA), a hybrid orthogonal quadrupole time-of-flight massspectrometer, was used for LC/MS/MS analysis. The Q-TOF MICRO™ is fullymicroprocessor controlled using MASSLYNX™ software version 4.1 (WatersMicromass MS Technologies, Milford, Mass., USA). The Q-TOF MICRO™ wasfitted with an ULTIMATE™ capillary and nano-flow HPLC system, which wascoupled with a FAMOS™ micro autosampler and a SWITCHOS™ II columnswitching device (LCPackings/Dionex, Sunnyvale, Calif., USA) forconcentrating and desalting samples. Samples were loaded onto a guardcolumn (300 μm ID×5 cm, PEPMAP™ C18) fitted in the injection loop andwashed with 0.1% formic acid in water at 40 μl per minute for 2 minutesusing a Switchos II pump. Peptides were separated on a 75 μm ID×15 cm,C18, 3 μm, 100 Å PEPMAP™ nanoflow fused capillary column (LC Packings,San Francisco, Calif., USA) at a flow rate of 175 nl/minute from a splitflow of 175 μl/minute using a NAN-75 calibrator (Dionex, Sunnyvale,Calif., USA). A step elution gradient of 5% to 80% acetonitrile in 0.1%formic acid was applied over a 45 minute interval. The column eluent wasmonitored at 215 nm and introduced into the Q-TOF MICRO™ through anelectrospray ion source fitted with the nanospray interface.

Data was acquired in survey scan mode from a mass range of m/z 400 to1990 with switching criteria for MS to MS/MS to include an ion intensityof greater than 10.0 counts per second and charge states of +2, +3, and+4. Analysis spectra of up to 4 co-eluting species with a scan time of1.9 seconds and inter-scan time of 0.1 seconds could be obtained. A conevoltage of 45 volts was typically used and the collision energy wasprogrammed to be varied according to the mass and charge state of theeluting peptide and in the range of 10-60 volts. The acquired spectrawere combined, smoothed, and centered in an automated fashion and a peaklist generated. The peak list was searched against selected databasesusing PROTEINLYNX™ Global Server 2.2.05 software (Waters Micromass MSTechnologies, Milford, Mass., USA) and PEAKS Studio version 4.5 (SP1)(Bioinformatic Solutions Inc., Waterloo, Ontario, Canada). Results fromthe PROTEINLYNX™ and PEAKS Studio searches were evaluated andun-identified proteins were analyzed further by evaluating the MS/MSspectra of each ion of interest and de novo sequence was determined byidentifying the y and b ion series and matching mass differences to theappropriate amino acid.

A peptide sequence was obtained from a multiple charged peptide ionrecovered from the in-gel digested 30 kDa polypeptide gel band. A doublycharged tryptic peptide ion of 514.772 m/z sequence was determined to beAsn-Ser-Tyr-Pro-Gly-Tyr-[Asp or Asn]-Gly-Arg (SEQ ID NO: 4).

Example 2 Humicola insolens DSM 1800 Genomic DNA Extraction

Humicola insolens DSM 1800 was grown on PDA plates at 45° C. toconfluence. Three 4 mm² squares were cut from the PDA plates, inoculatedinto 25 ml of YP medium containing 2% glucose in a baffled 125 ml shakeflask, and incubated at 41° C. with shaking at 200 rpm for 2 days.Mycelia were harvested by filtration using MIRACLOTH® (Calbiochem, LaJolla, Calif., USA), washed twice in deionized water, and frozen underliquid nitrogen. Frozen mycelia were ground, by mortar and pestle, to afine powder, and total DNA was isolated using a DNEASY® Plant Maxi Kit(QIAGEN Inc., Valencia, Calif., USA).

Example 3 Isolation of a Partial Fragment of an acetylxylan esteraseGene from Humicola insolens DSM 1800

Using the Consensus-Degenerate Hybrid Oligonucleotide Primer Program(CODEHOP; Rose et al., 1998, Nucleic Acids Research 26: 1628-1635),degenerate primers, shown below, were designed to the identified peptidedescribed in Example 1.

Primer HiFAE-degF (SEQ ID NO: 5) 5′-WSNYTNCARCARGTNTGGAAYTGGGGNGCNAAY-3′Protein translation for degenerate primer HiFAE-degF: (SEQ ID NO: 6)XXQQVWNWGA Primer HiFAE-degR: (SEQ ID NO: 7)5′-GGCGGCGGCCGTCRTANCCNGGRTA-3′Protein translation for degenerate primer HiFAE-degR: YPGYDGRR

To obtain the initial DNA fragment of the Humicola insolens acetylxylanesterase gene, the amplification reaction (25 μl) was composed of 117 ngof Humicola insolens DSM 1800 genomic DNA as template, 0.4 mM each ofdATP, dTTP, dGTP, and dCTP, 50 pmol each of primer HiFAE-degR and primerHiFAE-degF, 1× ADVANTAGE® GC-Melt LA Buffer (Clontech Laboratories,Inc., Mountain View, Calif., USA), and 1.25 units of ADVANTAGE® GCGenomic Polymerase Mix. The amplification was performed using anEPPENDORF® MASTERCYCLER® 5333 (Eppendorf Scientific, Inc., Westbury,N.Y., USA) programmed for pre-denaturing at 94° C. for 1 minute; 30cycles each at a denaturing temperature of 94° C. for 30 seconds;annealing temperature of 60° C. for 30 seconds; elongation at 72° C. for90 seconds; and final elongation at 72° C. for 5 minutes.

The reaction products were isolated by 1.0% agarose gel electrophoresisin TBE (10.8 g of Tris base, 5.5 g of boric acid and 4 ml of 0.5 M EDTApH 8.0 per liter) buffer. A PCR product band of approximately 1.1 kb wasexcised from the gel, purified using a QIAQUICK® Gel Extraction Kit(QIAGEN Inc., Valencia, Calif., USA) according to the manufacturer'sinstructions, and sequenced. Based on the sequencing it was found thatprimer HiFAE-degF did not bind during the amplification, while primerHiFAE-degR bound to both ends. A partial sequence was obtained whichencoded a peptide fragment that was homologous to a putative acetylxylanesterase from Neosartorya fischeri (Uniprot:A1DBP9).

Example 4 Identification of a Full-Length Humicola insolens acetylxylanesterase Gene

A full-length acetylxylan esterase gene was identified from Humicolainsolens DSM 1800 using a GENOMEWALKER™ Universal Kit (ClontechLaboratories, Inc., Mountain View, Calif., USA) according to themanufacturer's instructions. Briefly, total genomic DNA from Humicolainsolens DSM 1800 was digested separately with four differentrestriction enzymes (Dra I, Eco RV, Pvu II, and Stu I) that leave bluntends. Each batch of digested genomic DNA was then ligated separately tothe GENOMEWALKER™ Adaptor (Clontech Laboratories, Inc., Mountain View,Calif., USA) to create four libraries. These four libraries were thenemployed as templates in PCR reactions using two gene-specific primersshown below, one for a primary PCR and one for a secondary PCRamplifying downstream of the fragment through the 3′ end encoding theC-terminus of the acetylxylan esterase. Based on sequence homology toother acetylxylan esterases, it appeared the 5′ end encoding theN-terminus of the acetylxylan esterase was contained within the initialfragment described in Example 3. The following primers were designedbased on the partial acetylxylan esterase gene sequence from Humicolainsolens obtained as described in Example 3:

Primer HinsAXE_GSP1_F1 (primary): (SEQ ID NO: 8)5′-CTACACGGGCACTGTTGCTGGCTGGAA-3′ Primer HinsAXE_GSP2_F3 (secondary):(SEQ ID NO: 9) 5′-ACACTGGGCCAGGACGGCGCTCGATAT-3′

The primary amplifications were composed of 1 μl (approximately 6 ng) ofeach library as template, 0.4 mM each of dATP, dTTP, dGTP, and dCTP, 10pmol of Adaptor Primer 1 (Clontech Laboratories, Inc., Mountain View,Calif., USA), 50 pmol of primer Hins_AXE_GSP1_F1, 1× ADVANTAGE® GC-MeltLA Buffer (Clontech Laboratories, Inc., Mountain View, Calif., USA), and1.25 units of ADVANTAGE® GC Genomic Polymerase Mix in a final volume of25 μl. The amplifications were performed using an EPPENDORF®MASTERCYCLER® 5333 programmed for pre-denaturing at 95° C. for 1 minute;5 cycles each at a denaturing temperature of 95° C. for 25 seconds;annealing and elongation at 72° C. for 5 minutes; 7 cycles each at adenaturing temperature of 95° C. for 25 seconds; annealing andelongation at 72° C. for 5 minutes; 32 cycles each at a denaturingtemperature of 95° C. for 25 seconds; annealing and elongation at 67° C.for 5 minutes; and a final elongation at 67° C. for 7 minutes.

The secondary amplifications were composed of 1 μl of each primary PCRproduct as template, 0.4 mM each of dATP, dTTP, dGTP, and dCTP, 10 pmolof Adaptor Primer 2 (Clontech Laboratories, Inc., Mountain View, Calif.,USA), 50 pmol of primer Hins_AXE_GSP2_F3, 1× ADVANTAGE® GC-Melt LABuffer, and 1.25 units of ADVANTAGE® GC Genomic Polymerase Mix in afinal volume of 25 μl. The amplifications were performed using anEPPENDORF® MASTERCYCLER® 5333 programmed for pre-denaturing at 95° C.for 1 minute; 5 cycles each at a denaturing temperature of 95° C. for 25seconds; annealing and elongation at 72° C. for 5 minutes; 20 cycleseach at a denaturing temperature of 95° C. for 25 seconds; annealing andelongation at 67° C. for 5 minutes; and final elongation at 67° C. for 7minutes.

The reaction products were isolated by 1.0% agarose gel electrophorsisin TBE buffer. From the Pvu II library, 1 kb and 1.8 kb products wereexcised from the gel, purified using a QIAQUICK® Gel Extraction Kit(QIAGEN, Valencia, Calif., USA) according to the manufacturer'sinstructions, and sequenced.

DNA sequencing of the PCR fragments was performed with a Perkin-ElmerApplied Biosystems Model 377 XL Automated DNA Sequencer usingdye-terminator chemistry (Giesecke et al., 1992, supra) and primerwalking strategy. Adaptor Primer 2 and primer Hins_AXE_GSP2_F3 were usedfor sequencing.

Nucleotide sequence data were scrutinized for quality and all sequenceswere compared to each other with assistance of PHRED/PHRAP software(University of Washington, Seattle, Wash., USA). The PCR fragmentsequence results were compared and aligned with the partial acetylxylanesterase gene sequence from Humicola insolens described in Example 3. Agene model was constructed based on the gene fragments obtained in thisExample and in Example 3 allowing determination of the 5′ and 3′ ends ofthe gene with other homologous acetylxylan esterases.

Example 5 Cloning of the Humicola insolens acetylxylan esterase Gene andConstruction of an Aspergillus niger Expression Vector

Two synthetic oligonucleotide primers shown below were designed to PCRamplify the Humicola insolens acetylxylan esterase gene from the genomicDNA prepared in Example 2. An InFusion Cloning Kit (BD Biosciences, PaloAlto, Calif., USA) was used to clone the fragment directly into theexpression vector pBM120a (WO 2006/078256).

HinsAXEBDinfnterm: (SEQ ID NO: 10)5′-ACACAACTGGCCATGAAGGTCCCGACTCTCATCTCG-3′ HinsAXEBDinfCtermendPacI:(SEQ ID NO: 11) 5′-CAGTCACCTCTAGTTATTACAGGCACTGAGAGTACC-3′Bold letters represent coding sequence. The remaining sequence ishomologous to the insertion sites of pBM120a.

Fifty picomoles of each of the primers above were used in a PCR reactioncomposed of 80 ng of Humicola insolens genomic DNA, 1× ADVANTAGE®GC-Melt LA Buffer, 0.4 mM each of dATP, dTTP, dGTP, and dCTP, and 1.25units of ADVANTAGE® GC Genomic Polymerase Mix in a final volume of 25μl. The amplification was performed using an EPPENDORF® MASTERCYCLER®5333 programmed for 1 cycle at 94° C. for 1 minute; 30 cycles each at94° C. for 30 seconds, 58° C. for 30 seconds, and 72° C. for 90 seconds;and a final elongation at 70° C. for 5 minutes. The heat block then wentto a 4° C. soak cycle.

The reaction products were isolated by 1.0% agarose gel electrophoresisin TBE buffer where an approximately 1.2-1.3 kb product band was excisedfrom the gel, and purified using a QIAQUICK® Gel Extraction Kitaccording to the manufacturer's instructions.

Plasmid pBM120a was digested with Nco I and Pac I, isolated by 1.0%agarose gel electrophoresis in TBE buffer, and purified using aQIAQUICK® Gel Extraction Kit according to the manufacturer'sinstructions.

The gene fragment and the digested vector were ligated together using anInFusion Cloning Kit resulting in pMMar6 (FIG. 2) in which transcriptionof the acetylxylan esterase gene was under the control of a hybrid ofpromoters from the genes for Aspergillus niger neutral alpha-amylase andAspergillus oryzae triose phosphate isomerase (NA2-tpi promoter). Theligation reaction (20 μl) was composed of 1× InFusion Buffer (BDBiosciences, Palo Alto, Calif., USA), 1× BSA (BD Biosciences, Palo Alto,Calif., USA), 1 μl of InFusion enzyme (diluted 1:10) (BD Biosciences,Palo Alto, Calif., USA), 106 ng of pBM120a digested with Nco I and PacI, and 208 ng of the purified Humicola insolens acetylxylan esterase PCRproduct. The reaction was incubated at room temperature for 30 minutes.Two μl of the reaction was used to transform E. coli XL10 SOLOPACK® GoldSupercompetent cells (Stratagene, La Jolla, Calif., USA) according tothe manufacturer's instructions. An E. coli transformant containingpMMar6 was detected by restriction digestion and plasmid DNA wasprepared using a BIOROBOT® 9600 (QIAGEN Inc., Valencia, Calif., USA).The Humicola insolens acetylxylan esterase gene insert in pMMar6 wasconfirmed by DNA sequencing with a Perkin-Elmer Applied Biosystems Model377 XL Automated DNA Sequencer using dye-terminator chemistry (Gieseckeet al., 1992, supra) and primer walking strategy. Primer 996271 Na2tpipromoter fwd and primer 996270 AMG rev, shown below, were used forsequencing.

996271 Na2tpi promoter fwd: (SEQ. ID NO: 12)5′-ACTCAATTTACCTCTATCCACACTT-3′ 996270 AMG rev: (SEQ. ID NO: 13)5′-CTATAGCGAAATGGATTGATTGTCT-3′

A clone containing pMMar6 was picked into 2×50 ml of LB mediumcontaining 100 μg of ampicillin per ml and grown overnight in 250 mlglass flasks at 37° C. with shaking at 200 rpm. Plasmid pMMar6 wasisolated using a QIAGEN® Midi Kit according to the manufacturer'sinstructions. Plasmid pMMar6 was digested with Pme I, isolated by 1.0%agarose gel electrophoresis in TBE buffer, and the fragment containingthe acetylxylan esterase gene was purified using a QIAQUICK® GelExtraction Kit according to the manufacturer's instructions inpreparation for transforming Aspergillus niger MBin120 protoplasts. Thesame approximately 1.2-1.3 kb PCR fragment was cloned into pCR®2.1-TOPO® vector (Invitrogen, Carlsbad, Calif., USA) using a TOPO® TACLONING Kit (Invitrogen, Carlsbad, Calif., USA), to generate pHinsAXE2(FIG. 3). The Humicola insolens acetylxylan esterase gene insert inpHinsAXE2 was confirmed by DNA sequencing. E. coli pHinsAXE2 wasdeposited with the Agricultural Research Service Patent CultureCollection, Northern Regional Research Center, Peoria, Ill., USA, onNov. 20, 2007.

Example 6 Characterization of the Humicola insolens Genomic SequenceEncoding a Family CE1 acetylxylan esterase (AXE2)

Nucleotide sequence data (Example 5) were scrutinized for quality andall sequences were compared to each other with assistance of PHRED/PHRAPsoftware (University of Washington, Seattle, Wash., USA).

The nucleotide sequence (SEQ ID NO: 1) and deduced amino acid sequence(SEQ ID NO: 2) are shown in FIGS. 1A and 1B. The genomic fragmentencodes a polypeptide of 377 amino acids, interrupted by 2 predictedintrons of 73 by and 62 bp. The % G+C content of the full-length codingsequence and the mature coding sequence are 60.4% and 60.5%,respectively. Using the SignalP software program (Nielsen et al., 1997,Protein Engineering 10: 1-6), a signal peptide of 19 residues waspredicted. The predicted mature protein contains 358 amino acids with amolecular mass of 38.5 kDa. A predicted esterase polyhydroxybutyratedepolymerase domain occurs at amino acids 43 to 257 and a predictedcellulose-binding domain at amino acids 341 to 377. Based on the deducedamino acid sequence, the acetylxylan esterase appears to fall into thecarbohydrate esterase Family CE1 according to Coutinho and Henrissat,1999, supra.

A comparative pairwise global alignment of amino acid sequences wasdetermined using the Needleman-Wunsch algorithm (Needleman and Wunsch,1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program ofEMBOSS with gap open penalty of 10, gap extension penalty of 0.5, andthe EBLOSUM62 matrix. The alignment showed that the deduced amino acidsequence of the mature polypeptide of the Humicola insolens Family CE1acetylxylan esterase gene shared 72.4% identity (excluding gaps) to thededuced amino acid sequence of a Chaetomium gracile acetylxylan esterase(GeneSeqP accession number AAB82124).

Example 7 Transformation and Expression of the Humicola insolens FamilyCE1 acetylxylan esterase Gene in Aspergillus niger MBin120

The Humicola insolens Family CE1 acetylxylan esterase gene was expressedin Aspergillus niger MBin120. Aspergillus niger MBin120 protoplasts wereprepared according to the method of Christensen et al., 1988,Bio/Technology 6: 1419-1422. Five μg of Pme I digested pMMar6 were usedto transform Aspergillus niger MBin120.

The transformation of Aspergillus niger MBin120 with the Pme I digestedpMMar6 yielded approximately 45 transformants. Twenty-five transformantswere isolated to individual COVE A urea-acetamide+plates. Two 3 mmsquare agar plugs were cut from the confluent COVE Aurea-acetamide+plates of the 25 transformants and inoculated separatelyinto 25 ml of M410 medium in 125 ml plastic shake flasks and incubatedat 34° C. with shaking at 250 rpm. After 5 days incubation, 6 μl ofsupernatant from each culture were analyzed on a CRITERION™ 8-16%Tris-HCl SDS-PAGE gel with a CRITERION® Cell (Bio-Rad Laboratories,Inc., Hercules, Calif., USA), according to the manufacturer'sinstructions. The resulting gel was stained with BIO-SAFE™ Coomassiestain.

SDS-PAGE profiles of the cultures showed that approximately half of thetransformants had a major band of approximately 50 kDa. One transformantdesignated Aspergillus niger MMar204 was chosen for expression of theHumicola insolens polypeptide having acetylxylan esterase activity inAspergillus niger.

Example 8 Fermentation of Aspergillus niger MMar204

Shake flask medium was composed per liter of 70 g of sucrose and 100 gof soy concentrate. Trace metals solution was composed per liter of 13.8g of FeSO₄.7H₂O, 14.3 g of ZnSO₄.7H₂O, 11.6 g of MnSO₄.H₂O, 2.5 g ofCuSO₄.5H₂O, 0.5 g of NiCl₂.6H₂O and 3.3 g of citric acid monohydrate.

One hundred ml of shake flask medium were added to each of four 500 mlshake flasks. The shake flasks were each inoculated with 200 μl from aglycerol spore stock of Aspergillus niger MMar204 and incubated at 30°C. on an orbital shaker at 220 rpm for 72 hours. Fifty ml of the shakeflask broth from each of the four shake flasks were used to inoculate a3 liter fermentation vessel.

Fermentation batch medium was composed per liter of 250 g of glucose, 5g of (NH₄)₂SO₄, 2.5 g of KH₂PO₄, 0.5 g of CaCl₂.2H₂O, 2 g of MgSO₄.7H₂O,3 g of K₂SO₄, 1 g of citric acid, 1 ml of anti-foam, and 0.75 ml oftrace metals solution. The trace metals solution was composed per literof 13.8 g of FeSO₄.7H₂O, 14.3 g of ZnSO₄.7H₂O, 11.6 g of MnSO₄.H₂O, 2.5g of CuSO₄.5H₂O, 0.5 g of NiCl₂.6H₂O, and 3.3 g of citric acidmonohydrate. Fermentation feed medium was composed per kilogram of 406 gof maltose, 0.5 g of citric acid monohydrate, and 1 ml of anti-foam.

A total of 2 liters of the fermentation batch medium was added to anApplikon Biotechnology two liter glass jacketed fermentor (ApplikonBiotechnology, Schiedam, Netherlands). Fermentation feed medium wasdosed at a rate of 0 to 4 g/l/hr for a period of 185 hours. Thefermentation vessel was maintained at a temperature of 34° C. and pH wascontrolled using an Applikon 1030 control system (ApplikonBiotechnology, Schiedam, Netherlands) to a set-point of 5.1+/−0.1. Airwas added to the vessel at a rate of 1 vvm and the broth was agitated byRushton impeller rotating at 1100 rpm. At the end of the fermentation,whole broth was harvested from the vessel and centrifuged at 3000×g toremove the biomass. The supernatant was sterile filtered and stored at 5to 10° C.

Example 9 Purification of the Humicola insolens acetylxylan esterase(AXE2)

Supernatant of the fermentation broth described in Example 8 was firstbuffer-exchanged into 20 mM MES pH 6 and concentrated using a PallFiltron tangential flow filtration system consisting of an Ultrapump II,an ULTRARESERVOIR™ 5L, and an ULTRASETTE™ 10K Omega tangential flowfiltration membrane with a 10,000 Da molecular weight cut-off (PallCorporation, East Hills, N.Y., USA). The resulting buffer-exchangedmaterial (150 ml) was then purified over 120 ml of SP SEPHAROSE™ BigBeads resin (GE Healthcare, Piscataway, N.J., USA) equilibrated with 20mM MES pH 6, and then eluted with a linear gradient of 0-1 M sodiumchloride. Fractions were collected and monitored at 280 nm. A 2.5 μlaliquot of the fractions having UV absorbance at 280 nm were analyzed ona CRITERION™ 8-16% Tris-HCl SDS-PAGE gel according to the manufacturer'ssuggested conditions. PRECISION PLUS PROTEIN™ Standards were used asmolecular weight markers. The gel was stained with BIO-SAFE™ Coomassiestain. Fractions showing a band at 55 kDa, corresponding to the Humicolainsolens acetylxylan esterase, were combined to yield purifiedacetylxylan esterase (130 ml) of greater than 90% purity.

The Humicola insolens acetylxylan esterase was assayed for enzymeactivity using p-nitrophenylacetate as substrate (Sigma-Aldrich Chemicalco., Inc., St Louis, Mo., USA). Activity assays were performed in a96-well COSTAR® microtiter plate (Corning Inc., Corning, N.Y., USA). A100 mM p-nitrophenylacetate solution was initially prepared in DMSO, andthen diluted to a 1 mM solution in 50 mM sodium acetate pH 5.0 with0.01% TWEEN® 20. The enzyme reaction was then initiated by adding analiquot of the purified Humicola insolens acetylxylan esterase to the 1mM p-nitrophenylacetate suspension, resulting in a final substrateconcentration of 0.5 mM p-nitrophenylacetate. The reaction was allowedto proceed for 10 minutes at ambient temperature (25° C.), at which time1 M Tris-HCl pH 8.0 was added, and the amount of p-nitrophenolate anionreleased was determined by an increase in absorbance at 405 nm using aSPECTRAMAX™ 340 PC plate reader (Molecular Devices, Sunnyvale, Calif.,USA). Protein concentration of the purified was determined using aMicroplate BCA™ Protein Assay Kit (Pierce, Rockford, Ill., USA). Oneunit of acetylxylan esterase activity is defined as the amount of enzymecapable of releasing 1 μmole of p-nitrophenolate anion per minute at pH5, 25° C.

The Humicola insolens acetylxylan esterase was determined to have anactivity of 15.4 units per mg of enzyme.

Example 10 Thermostability of Humicola insolens acetylxylan esterase

The thermostability of the purified Humicola insolens polypeptide havingacetylxylan esterase activity (Example 9) was determined by differentialscanning calorimetry (DSC) using a A VP-DSC (MicroCal Inc., Northampton,Mass., USA) according to the manufacturer's instructions in 50 mM sodiumacetate pH 5.0.

The thermal denaturation temperature, Td, was taken as the top of thedenaturation peak (major endothermic peak) in a thermogram (Cp vs. T)obtained after heating of the enzyme solution at a programmed heatingrate of 90° C. per hour beginning at 20° C. The Td for the acetylxylanesterase under these conditions was 71(+/−1)° C.

Example 11 Effect of Humicola insolens acetylxylan esterase onhydrolysis of Pretreated Corn Fiber

The effect of Humicola insolens acetylxylan esterase on hydrolysis ofpretreated corn fiber was evaluated. Corn fiber is a fraction from thewet milling of corn kernels. Corn fiber is the seed coat and residualendosperm left after starch is removed and further processed. Corn fiberwas pretreated by autoclaving at 140° C. for 150 minutes. The amount ofarabinose, glucose and xylose in the substrate was determined to be 175,317, and 261 g per kg dry matter.

Arabinose and xylose were determined by carbohydrate hydrolysis usingdilute hydrochloric acid. The pretreated corn fiber was transferred to125 ml conical flasks and diluted to contain approximately 10% drymatter. The corn fiber sample was preheated at 100° C. in an oil bath.Hydrolysis was started by adding 5 ml of 2 M hydrochloric acid for 2hours at 100° C. After incubation the flasks were cooled on ice andneutralized with 4 M sodium hydroxide. Samples were filtered with aMINISART® 0.2 micron syringe filter (Sartorius AG, Goettingen, Germany)and analyzed for arabinose and xylose on a DIONEX BIOLC® System (DionexCorporation, Sunnyvale, Calif., USA). Glucose was determined bysubjecting the pretreated sample of corn fiber to a two step sulfuricacid hydrolysis. Three ml of 72% sulfuric acid was added toapproximately 300 mg of dried corn fiber in pressure tubes (Ace Glass,Inc., Vineland, N.J., USA). Samples were mixed and placed in a waterbath at 30° C. for 60 minutes. Samples were stirred every 5 to 10minutes. After 60 minutes the samples were removed and 84 ml ofdeionized water was added. Samples were placed in an autoclave andheated for 1 hour at 121° C. After cooling the samples were filtered toremove remaining solids and neutralized by addition of calciumcarbonate.

Glucose concentration was determined with a DIONEX® BIOLC® Systemaccording to the following method. Samples (10 μl) were loaded onto aDIONEX BIOLC® System equipped with a DIONEX® CARBOPAC™ PA1 analyticalcolumn (4×250 mm) (Dionex Corporation, Sunnyvale, Calif., USA) combinedwith a CARBOPAC™ PA1 guard column (4×50 mm) (Dionex Corporation,Sunnyvale, Calif., USA). The monosaccharides were separatedisocratically with 10 mM potassium hydroxide at a flow rate of 1 ml perminute and detected by a pulsed electrochemical detector in the pulsedamperiometric detection mode. The potential of the electrode wasprogrammed for +0.1 volt (t=0-0.4 second) to −2.0 volt (t=0.41-0.42second) to 0.6 volt (t=0.43 second) and finally −0.1 volt (t=0.44-0.50second), while integrating the resulting signal from t=0.2-0.4 second. Amixture of arabinose, galactose, glucose, and xylose (concentration ofeach component: 0.0050-0.075 g per liter) was used as standard.

The hydrolysis of the pretreated corn fiber was conducted with aTrichoderma reesei cellulolytic protein composition (Trichoderma reeseibroth comprising Thermoascus aurantiacus GH61A polypeptide havingcellulolytic enhancing activity and Aspergillus oryzae beta-glucosidasefusion; PCT/US2008/065417) and a Trichoderma reesei beta-xylosidase. TheTrichoderma reesei beta-xylosidase was obtained recombinantly byexpression in Aspergillus oryzae as described in Rasmussen et al., 2006,Biotechnology and Bioengineering 94: 869-876 using standard cultivationmethods for Aspergillus oryzae. The Humicola insolens acetylxylanesterase was obtained as described in Example 9.

The hydrolysis of the pretreated corn fiber was performed in 2 mlEPPENDORF® tubes (Eppendorf AG, Germany) at a temperature of 50° C. anda pH of 5.0 in 50 mM succinic acid. Samples were incubated in aTHERMOMIXER® Comfort (Eppendorf AG, Germany) that subjected each samplewith constant heating and mixing. The substrate amount used was 2.5 w/w% in a total sample volume of 2 ml. The acetylxylan esterase fromHumicola insolens was added at an enzyme loading of 1 mg enzyme per g ofdry matter on top of both the Trichoderma reesei cellulolytic proteincomposition and the Trichoderma reesei beta-xylosidase. The Trichodermareesei cellulolytic protein composition was added at a loading of 5 mgenzyme per g of dry matter and the Trichoderma reesei beta-xylosidase ata loading of 1 mg enzyme per g of dry matter. Hydrolysis was terminatedafter 24 hours by heating the samples for 10 minutes at 100° C. in aheat block (Techne Inc., Burlington N.J., USA).

Quantification of acetic acid was performed by high pressure liquidchromatography using two AMINEX® HPX-87H columns (Bio-Rad Laboratories,Hercules, Calif., USA) coupled in series with a pre-column (Micro-GuardCation H Refill Cartridges, Bio-Rad Laboratories, Hercules, Calif., USA)with a WATERS® 515 Pump, WATERS® MPSA Millipore, WATERS® 717 PlusAutosampler, WATERS® Column Heater Module and WATERS® 2410 RI detector(Waters Corporation, Milford, Mass., USA). The chromatography wasperformed at 60° C. with a flow of 0.4 ml/minute of 0.005 M sulfuricacid.

Conversion was calculated by determining the amount of sugars releasedfrom the substrate as a percentage of what was added from the startusing the formula below. T-tests were performed with a two taileddistribution and equal variance of sample data.

Conversion (%)=(Sugar amount in hydrolysate/Sugar amount in addedsubstrate)×100

Comparing the conversion of pretreated corn fiber when adding theacetylxylan esterase from Humicola insolens at an enzyme loading of 1 mgof enzyme per gram dry matter together with 1 mg enzyme per g of drymatter of Trichoderma reesei beta-xylosidase and 5 mg enzyme per g ofdry matter of Trichoderma reesei cellulolytic protein composition tojust adding 1 mg enzyme per g of dry matter of beta-xylosidase fromTrichoderma reesei and 5 mg enzyme per g of dry matter of Trichodermareesei cellulolytic protein composition demonstrated a significant(P≦0.0519) increase in relative conversion from 100.0 to 109.9 (Table1).

TABLE 1 Relative total Standard Samples conversion deviation T-testTrichoderma reesei cellulolytic 100.0 3.2 0.0519 protein composition andTrichoderma reesei beta- xylosidase Trichoderma reesei cellulolytic109.9 3.4 protein composition, Trichoderma reesei beta- xylosidase, andHumicola insolens acetylxylan esterase

The release of acetic acid from the substrate increased significantly(P≦0.0004) from 100.0 to 236.0 by adding the Humicola insolensacetylxylan esterase to the combination of Trichoderma reeseicellulolytic protein composition and the Trichoderma reeseibeta-xylosidase (Table 2).

TABLE 2 Relative release Standard Samples of acetic acid deviationT-test Trichoderma reesei cellulolytic 100.0 10.0 0.0004 proteincomposition and Trichoderma reesei beta- xylosidase Trichoderma reeseicellulolytic 236.0 2.8 protein composition, Trichoderma reesei beta-xylosidase, and Humicola insolens acetylxylan esterase

Example 12 Effect of Humicola insolens acetylxylan esterase on theHydrolysis of D-xylose tetraacetate

The effect of Humicola insolens acetylxylan esterase on the hydrolysisof D-xylose tetraacetate was evaluated. The Humicola insolensacetylxylan esterase was obtained as described in Example 9.

Hydrolysis of D-xylose tetraacetate (Benn Chemicals, Dielsdorf,Switzerland) was performed in 1.5 ml EPPENDORF® tubes at a temperatureof 50° C. and a pH of 5.0 in 50 mM succinic acid for 48 hours. Sampleswere incubated in a THERMOMIXER® Comfort that subjected each sample withconstant heating and mixing. The substrate amount used was 1 ml at aconcentration of 1 w/w % of D-xylose tetraacetate. The control sample (1ml of substrate) was compared with the Humicola insolens acetylxylanesterase sample (1 ml of substrate+7 μl of enzyme). The Humicolainsolens acetylxylan esterase was added at an enzyme loading of 0.5 mgHumicola insolens acetylxylan esterase/g dry solids. Hydrolysis wasterminated after 48 hours by heating the samples for 10 minutes at 100°C. in a heat block.

The amount of acetate was analyzed by HPLC as described in Example 11.Addition of 0.5 mg of Humicola insolens acetylxylan esterase to 1 ml ofsubstrate (1 w/w % of D-xylose tetraacetate) resulted in a calculatedrelease of 89.2 μmol/ml acetate (Table 3). The release of acetate byHumicola insolens acetylxylan esterase was calculated from theconcentrations of the control sample (1.9 μmol/ml) and the Humicolainsolens acetylxylan esterase sample (91.1 μmol/ml).

TABLE 3 Concentration of acetate Enzyme released acetate Samples(μmol/ml) (μmol/ml) Control 1.9 Humicola insolens 91.1 89.2 acetylxylanesterase

Deposit of Biological Material

The following biological material has been deposited under the terms ofthe Budapest Treaty with the Agricultural Research Service PatentCulture Collection (NRRL), Northern Regional Research Center, Peoria,Ill., USA, and given the following accession number:

Deposit Accession Number Date of Deposit E. coli pHinsAXE2 NRRL B-50076Nov. 20, 2007

The strain has been deposited under conditions that assure that accessto the culture will be available during the pendency of this patentapplication to one determined by foreign patent laws to be entitledthereto. The deposit represents a substantially pure culture of thedeposited strain. The deposit is available as required by foreign patentlaws in countries wherein counterparts of the subject application, orits progeny are filed. However, it should be understood that theavailability of a deposit does not constitute a license to practice thesubject invention in derogation of patent rights granted by governmentalaction.

The invention described and claimed herein is not to be limited in scopeby the specific aspects herein disclosed, since these aspects areintended as illustrations of several aspects of the invention. Anyequivalent aspects are intended to be within the scope of thisinvention. Indeed, various modifications of the invention in addition tothose shown and described herein will become apparent to those skilledin the art from the foregoing description. Such modifications are alsointended to fall within the scope of the appended claims. In the case ofconflict, the present disclosure including definitions will control.

1. An isolated polypeptide having acetylxylan esterase activity,comprising the mature polypeptide of SEQ ID NO:
 2. 2. The polypeptide ofclaim 1, consisting of the mature polypeptide of SEQ ID NO:
 2. 3. Thepolypeptide of claim 1, wherein the mature polypeptide is 20 to 377 ofSEQ ID NO:
 2. 4. The polypeptide of claim 1, which is encoded by apolynucleotide comprising or consisting of the mature polypeptide codingsequence of SEQ ID NO:
 1. 5. The polypeptide of claim 4, wherein themature polypeptide coding sequence is nucleotides 58 to 1266 of SEQ IDNO: 1
 6. The polypeptide of claim 1, which is encoded by thepolynucleotide contained in plasmid pHinsAXE2 which is contained in E.coli NRRL B-50076.
 7. An isolated polynucleotide that encodes thepolypeptide of claim
 1. 8. A nucleic acid construct comprising thepolynucleotide of claim 7 operably linked to one or more (several)control sequences that direct the production of the polypeptide in anexpression host.
 9. A recombinant host cell comprising the nucleic acidconstruct of claim
 8. 10. A method of producing the polypeptide of claim1, comprising: (a) cultivating a cell, which in its wild-type formproduces the polypeptide, under conditions conducive for production ofthe polypeptide; and (b) recovering the polypeptide.
 11. A method ofproducing the polypeptide of claim 1, comprising: (a) cultivating a hostcell comprising a nucleic acid construct comprising a polynucleotideencoding the polypeptide under conditions conducive for production ofthe polypeptide; and (b) recovering the polypeptide.
 12. A method ofproducing a mutant of a parent cell, comprising disrupting or deleting anucleotide sequence encoding the polypeptide of claim 1, which resultsin the mutant producing less of the polypeptide than the parent cell.13. A mutant cell produced by the method of claim
 12. 14. A method ofproducing the polypeptide of claim 1, comprising: (a) cultivating atransgenic plant or a plant cell comprising a polynucleotide encodingthe polypeptide under conditions conducive for production of thepolypeptide; and (b) recovering the polypeptide.
 15. A transgenic plant,plant part or plant cell transformed with a polynucleotide encoding thepolypeptide of claim
 1. 16. A double-stranded inhibitory RNA (dsRNA)molecule comprising a subsequence of the polynucleotide of claim 7,wherein optionally the dsRNA is a siRNA or a miRNA molecule.
 17. Amethod of inhibiting the expression of a polypeptide having acetylxylanesterase activity in a cell, comprising administering to the cell orexpressing in the cell the double-stranded inhibitory RNA molecule ofclaim
 16. 18. A method for degrading a xylan-containing material,comprising treating the xylan-containing material with the polypeptidehaving acetylxylan esterase activity of claim
 1. 19. The method of claim18, further comprising treating the xylan-containing material with axylan degrading enzyme.
 20. A composition comprising the polypeptide ofclaim 1.